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Abstract
The increased rate of contralateral prophylactic mastectomy (CPM) among women with
early stage unilateral breast cancer has raised concerns particularly with the lack of
evidence for a survival benefit related to the CPM procedure and with the low risk of
developing contralateral breast cancer among women with early stage sporadic breast
cancer. The purpose of this quantitative cross-sectional study, using normative decision
theory as the framework, was to assess the influence of the partner, physician, and media
on the decision of women with unilateral breast cancer who decided to undergo CPM.
Women with stage 0 to III early stage unilateral breast cancer ages 20-60 years old who
underwent CPM at MD Anderson Cancer Center in the U.S. between January of 2010
and December of 2017 were surveyed on factors influencing their decision to undergo
CPM. Logistic regression (binomial distribution with logit link) was used to analyze the
data. The results revealed that partners, physicians, and media all had significant
influence (p < 0.05) on the decision-making process of women with unilateral breast
cancer to undergo CPM. The findings of this study may inform policy by highlighting the
need for decision aids, programs, or tools that help women with unilateral breast cancer
make informed decisions that are evidence-based regarding the efficacy of CPM.
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Chapter 1: Introduction to the Study
Women with early stage unilateral breast cancer are electing to have contralateral
prophylactic mastectomy (CPM) to reduce the risk of developing a contralateral breast
cancer. In the United States, the CPM rate for the surgically treated women with stages I
to III unilateral breast cancer increased dramatically from 1998 to 2003 (Baker et al.,
2013). Another study showed that the rate of CPM among women with unilateral
invasive breast cancer increased from 2.2% in 1998 to 11% in 2011 (Jemal et al., 2015).
Breast cancer patients should understand the benefits versus the risks of CPM in order to
make informed decisions. The purpose of this study was to examine the influence of
physicians, partners, and media on the decision-making process of women with unilateral
early stage breast cancer who decided to undergo CPM. This study was needed because
breast cancer patients can be influenced by others and may not be making informed
decisions about engaging in this aggressive and irreversible procedure (CPM). This
chapter will include a discussion of the study background, problem statement, purpose of
study, research questions and hypotheses, theoretical framework, nature of the study,
definition of terms, assumptions, limitations and significance of the study.
Background of the Study
Contralateral prophylactic mastectomy (CPM) is a procedure that women may
choose in order to prevent breast cancer in the healthy breast. The rate of CPM in the
United States has more than doubled from 1.8% in 1998 to 4.5 % in 2003 (Tuttle,
Habermann, Grund, Morris, & Virnig, 2007). The trend of the increasing rate of CPM
among women with unilateral breast cancer has raised concern, particularly with the lack
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of evidence for a survival benefit related to the CPM procedure (Tracy, Rosenberg,
Dominici, & Partridge, 2013), and with the minimal (0.5%-0.75%) annual risk of women
with early stage sporadic breast cancer for developing contralateral breast cancer
(Brewster & Parker, 2011). Women might be choosing this procedure to ease their fear of
recurrence, and by believing that CPM may improve their quality of life; others might be
influenced by their physicians, partners, or even the media. In a small percentage of
women, CPM is performed because of cancer in both breasts (Komen, 2012). The
decision to undergo the CPM procedure should not be made without considerable thought
(Komen, 2012). The National Comprehensive Cancer Network (NCCN) guidelines are
discouraging women from considering CPM to help lower their incidence of developing
breast cancer in their healthy breast and recommending that this procedure should only
take place if women are considered at high risk of breast cancer (Komen, 2012).
Several clinical and pathological factors may be related to an increased risk for
developing contralateral breast cancer in women with unilateral breast cancer. Some of
these factors are young patient age, family history of breast cancer, chest radiation,
lobular type histology, and multicentric cancer (Tuttle et al., 2007). In addition, patients
who tested positive for BRCA1 and BRCA2 genetic mutations are at high risk for
developing contralateral breast cancer. However, for most women with early stage
sporadic unilateral breast cancer, the risk of a contralateral breast cancer is low (Brewster
& Parker, 2011).
The increased rate of CPM is concerning among the group of women with low
annual risk for developing contralateral breast cancer. CPM can greatly lower the risk of

3
developing breast cancer in the healthy breast but does not increase the overall survival
rate and is not usually recommended (Komen, 2012). Tuttle et al. (2007) shared in their
study that the effectiveness of CPM on reducing breast cancer mortality is still unclear
and they suggested that further studies are critically needed in order to evaluate the
patients’ decision-making process that leads patients to consider CPM. Several factors
can affect the decision-making process of women with unilateral breast cancer to undergo
CPM but a gap exists in the literature because few studies have examined the influence of
partner, physician and the media on the decision making process. The National Cancer
Institute is discouraging this aggressive and irreversible procedure by stating that it is
unnecessary for preventing contralateral breast cancer in most patients (NCI, 2007). The
Mayo Clinic study demonstrated that many women have had unnecessary surgery
(Siroky, 2012). This study was needed because the lack of information regarding the
clinical benefits of CPM for women with sporadic or early stage breast cancer, as well as
the influence of physicians, partner, or media on the CPM decision making process is a
major area of public health concern. While researchers may know the factors that are
influencing the decision-making process of women with unilateral breast cancer to
undergo CPM, research was needed in order to develop a decision quality tool that helps
women with unilateral breast cancer make an informed decision regarding their surgical
choice. The decision quality tool could be a brochure that includes but not limited to the
indication for the CPM procedure, the necessity and the medically unnecessary indication
of the procedure, doctor’s recommendation, the pro and cons of the procedure, the
complications, and frequently asked questions, as well as feedbacks from patients who
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did and did not choose CPM. The patient should have good knowledge regarding the
irreversible procedure so they can make a shared informed decision about their treatment
options.
Problem Statement
CPM is a procedure that women with unilateral breast cancer may choose because
the scientific evidence suggests it might prevent breast cancer in the healthy breast. There
are various reasons for the increase in CPM rates, but few studies have examined the
influence of partner, physician, as well as the media on the women's decision-making
process. Frost et al. (2005) identified in their study that the most frequently cited reasons
for women with unilateral breast cancer to undergo CPM included the physician advice
and the family history of breast cancer. Partners can also play a major role in the
decision-making process. Women-partner shared decision-making is vital especially
since the adjustment to body image after mastectomy can be a gradual and lengthy
process. Physician-patient communication is also critically important in patients
diagnosed with unilateral breast cancer. Women should be educated about their disease
and the available treatment options so that they can make informed decisions related to
their care.
The media may influence the decision-making process as well. The internet,
television, radio, and advertising are easily accessible by individuals and can affect
an individual’s decisions. The media sometimes quotes physicians, scientists,
researchers, and many experts on the latest medical developments, so it might be
difficult for people who do not have appropriate background knowledge to
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disagree. Some medical companies may also use famous people to advertise for
their products; these companies will publicize the fact that these celebrities agree
with their point of view, product, or procedure, possibly because they believe that
the general public holds celebrities in high regard. Some of the best-known
examples for this trend are two famous actresses, Christina Applegate and Angelina
Jolie. Christina Applegate was diagnosed with unilateral breast cancer in 2008 but
opted to remove her healthy breast along with the affected breast (OSU, 2010).
Applegate had a family history of breast cancer and tested positive for mutations in
the BRCA gene. Angelina Jolie, who also tested positive for mutations in the
BRCA1 gene, underwent a radical double mastectomy to lower her risk of
developing cancer (Park, 2013). Kamenova et al. (2014) study highlighted the
media’s overwhelming positive slant toward Angelina Jolie’s mastectomy while
overlooked the other factors in her case, the challenges of “celebrity medicine ,”
and how celebrities can influence people’s medical decisions. Media don’t usually
gives details regarding BRCA mutation and what it means. Researchers from the
University of Michigan analyzed 727 articles from major U.S. print publications
that covered celebrities’ breast cancer diagnoses and concluded that an increase in
rate of women with breast cancer choosing double mastectomy may be influenced
by media coverage of celebrities (Sabel & Dal Cin, 2016).
The BRCA mutations genetic test is not performed for every woman that is
at risk of developing breast cancer; it is usually recommended by physicians for
women of a younger age who may be at risk for developing breast cancer, or who
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have several family members diagnosed with breast cancer. BRCA mutation testing
is a very expensive test that can cost up to $3000 (Park, 2013) and insurance
companies require that patients meet a threshold for needing the BRCA test before
they consider covering its cost.
Despite knowing that CPM does not improve survival rate, many women with
unilateral breast cancer are choosing this procedure in order to ease their fear and
potentially extend their lives (Rosenberg et al., 2013). Rosenberg et al. (2013) suggested
that evidence-based decision-making interventions are needed in order to improve risk
communication. Several factors can affect the decision-making process of women
with unilateral breast cancer to undergo a CPM, but to what extent was the decision,
of a woman with unilateral breast cancer to have CPM influenced by the partner,
physician, and media? There are several reasons for the increased rate in CPM, but few
studies have examined the influence of partner, physician and the media on the decisionmaking process of women with unilateral breast cancer to undergo CPM. Breast cancer
patients can be influenced by others and may not be making informed decision about
engaging in this aggressive and irreversible procedure. Breast cancer patients should
understand the benefits versus the risks of CPM in order to make informed decisions.
This study is needed because the findings of the study could highlight the need for
developing a decision quality tool that helps women with early stage unilateral breast
cancer make informed decisions regarding their surgical choices and address an existing
gap in the literature. The decision quality tool can be a brochure that includes but is not
limited to the indication for the CPM procedure, the necessity and the medically
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unnecessary indication of the procedure, doctor’s recommendation, the pro and cons of
the procedure, the complications, and frequently asked questions, as well as feedback
from patients who did and did not choose CPM. The patient should have good knowledge
regarding the irreversible procedure so they can make a shared informed decision about
their treatment options.
Purpose of the Study
The purpose of this study was to assess the influence of the partner, physician,
and media on the decision of women with unilateral breast cancer who decided to
undergo CPM. The independent variables are the influence of partner, physician, and
media; the dependent variable is the decision to undergo CPM.
Research Questions and Hypotheses
The research questions and hypotheses for this study were as follows:
Research Question 1: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by partners?
H01: Partners have no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
H11: Partners have a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
Research Question 2: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by physicians?
H02: Physicians have no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
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H12: Physicians have a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
Research Question 3: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by the media?
H03: The media has no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
H13: The media has a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
Theoretical Framework
The decision theory was used as a theoretical framework to identify the impact of
physician, partner and media on the decision-making process of breast cancer women to
undergo CPM, as well as whether these women made the decision on their own, only by
the physician; or whether the women and physicians exchanged information and
preferences and made the decision together. By using the theoretical framework, the
results of the study might move beyond the original questions and framework and might
add something new to the body of the research.
Normative and Descriptive Decision Theories
The decision theory is founded on the connection between the rational preferences
with certain structural properties (Buchak, 2013). The components of these theorems can
be interpreted in different ways. Philosophy's interest in decision theory represents a
union between two different lines of thought; one is centered around the question on how
individuals ought to act, while the other is concerned with the action related to the actor’s
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mental states (Buchak, 2013). As a result, philosophy has adopted this theory in two
different uses, the normative use and the interpretive use. The subject of decision making
has been active in psychological inquiry since the beginning of experimental psychology
(Patel & Kaufman, 2002). Decision making research traces back to the 1940s and 50s
(Patel et al., 2002). It was first inspired by Van Neumann and Morgenstern's theory of
games (Patel et al., 2002). Social scientists in several different disciplines started to
advance the systematic study of decision making and developed abstract theoretical
models and conducted empirical studies (Patel et al., 2002). Other social science
disciplines, including economics, business, psychology, sociology, and political science,
dedicated significant effort in applying these models and refining them in order to
investigate different phenomena and develop related applications (Patel et al., 2002).
The normative theories of decision making are based on two main types of
models: the expected utility (EU) and the subjective expected utility (SEU; Patel et al.,
2002). The idea behind these two models is that when making a decision, "one should
maximize one's gain" (Patel et al., 2002, p. 55).The second type of model uses the notion
of conditional probability as expressed "in the subjectivist, personalist, or Bayesian
perspective" (Patel et al., 2002, p. 55). The aspects of these types of models are that they
lay the standards of comparing and improving actual human decision-making and provide
well defined mathematical models of rational decisions (Patel et al., 2002).
Shared Model of Decision-Making
The shared model of decision-making is the derivative of the normative decision
theory. It integrates the feature that patients are consumers of medical care and have the
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right to actively participate in the decision-making process concerning treatment choices
and risk reduction strategies (Elwyn et al., 2012). Shared decision-making (SDM) has
been defined as an approach in which physicians and patients jointly decide which
medical treatment option is best based on current evidence and patient’s preferences,
needs, and values (Elwyn et al., 2012). The normative decision theory includes an active
attempt in order to engage patient’s values in the decision-making process. In order to
accomplish this goal, patients are provided with decision aids such as informative
brochures, videos, computer programs, as well as physician’s inputs (Elwyn et al., 2012).
This model is conceptualized as providing the patient with both objective medical
information incorporated with their subjective values and opinions (Elwyn et al., 2012).
Nature of the Study
A quantitative cross-sectional survey design was used for this research. The
survey design provided a numeric description (see Creswell, 2009) of the factors that are
affecting the women decision to undergo CPM; as well as the influence of the partner,
physician, and the media, on the woman’s decision-making process. The survey for this
study consisted of 16 questions that were adopted and modified from the Prophylactic
Mastectomy Outcomes Study Survey (Geiger et al., 2006). Women with stage 0 to III
early stage unilateral breast cancer ages 20-60 years old who underwent CPM at MD
Anderson Cancer Center between January of 2010 and December of 2017 were the target
population for this study. Excluded from the study were women who (a) had bilateral
breast cancer before undergoing CPM; (b) had received any treatment for breast cancer
before their initial visit to MD Anderson; (d) had bilateral breast cancer before
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undergoing CPM; and (e) had incomplete documentation of diagnosis of breast cancer,
hormone receptor status or metastatic disease were excluded from the study. The
independent variables were the influence of partner, physician, and media; the dependent
variable was the decision to undergo CPM. Descriptive statistics were used to analyze the
characteristics of the patients, and binary outcomes modeled by logistic regression
(binomial distribution with logit link) was used in order to assess the influence of doctors,
partners and media on patient’s decision to have CPM. For each outcome, inclusion of
potential covariates was assessed by adding them to the model and comparing them to the
model without the covariate based upon the Akaike Information Criteria (AIC); models
including a covariate which did not improve (lower) the AIC with relation to the
intercept-only model, implicitly showing no evidence of significant association between
the outcome and that covariate.
Definition of Terms
The American Cancer Society website was used to define the following cancerrelated terms (American Cancer Society, 2014).
Advanced Cancer/metastasis: "a general term describing stages of cancer in
which the disease has spread from where it started (the primary site) to other parts of the
body" (American Cancer Society, 2014, para. 27).
AJCC Staging System: "American Joint Committee on staging system (also called
the TNM system), which is used to describe the extent of spread of many types of cancer,
typically with the number 0 (zero) and Roman numerals I through IV" (American Cancer
Society, 2014, para. 17).
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Atypia: "not normal; refers to the appearance of cancerous or pre-cancerous cells
under the microscope" (American Cancer Society, 2014, para. 70).
Bilateral: "on both right and left sides of the body" (American Cancer Society,
2014, para. 12).
Body image: "the way a person thinks about their body and how they think it
looks to others" (American Cancer Society, 2014, para. 24).
BRCA1: "a gene which, when damaged (mutated), puts a person at a higher risk
of developing breast, ovarian, and some other types of cancer when compared to people
who do not have this mutation"(American Cancer Society, 2014, para. 35).
BRCA2: "a gene which, when damaged (mutated), puts a person at a higher risk
of developing breast, ovarian, and some other types of cancer when compared to people
who do not have this mutation" (American Cancer Society, 2014, para. 36).
Breast Cancer: "cancer that starts in the breast. The most common types of cancer
are ductal carcinoma in situ, invasive ductal carcinoma, invasive lobular carcinoma,
medullary carcinoma, and Paget disease of the nipple. Lobular carcinoma in situ is
sometimes listed as non-invasive type of cancer, even though it is not a true cancer or
pre-cancer" (American Cancer Society, 2014, para. 39).
Breast implant: "a sac used to increase the breast size or restore the shape of a
breast after mastectomy (surgical removal of the breast). The sac is filled with silicone
gel (a synthetic material) or sterile saltwater (saline)" (American Cancer Society, 2014,
para. 41).
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Breast Self-Exam (BSE): "a way to check your own breasts for lumps or
suspicious changes" (American Cancer Society, 2014, para. 43).
Cancer: "a group of diseases which cause cells in the body to change and grow
out of control. Most types of cancer cells from a lump or mass called a tumor" (American
Cancer Society, 2014, para. 5).
Cancer cell: "a cell that divides and reproduces abnormally and can spread
throughout the body, crowding out normal cells and tissue. Cancer cells develop because
of damage to their deoxyribonucleic acid (DNA)" (American Cancer Society, 2014, para.
7).
Carcinoma in situ: "an early stage of cancer in which the cancer cells are only in
the layer of cells where they first began, and have not grown into nearby tissues in other
parts of the organ or spread to distant parts of the body" (American Cancer Society, 2014,
par AJCC Staging System a. 20).
Decision quality tool: The decision quality tool can be a brochure that includes
but not limited to the indication for the CPM procedure, the necessity and the medically
unnecessary indication of the procedure, doctor’s recommendation, the pro and cons of
the procedure, the complications, and frequently asked questions, as well as feedbacks
from patients who did and did not choose CPM. The patient should have good knowledge
regarding the irreversible procedure so they can make a shared informed decision about
their treatment options.
Fibrosis: "formation of scar-like tissues" (American Cancer Society, 2014).
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Invasive ductal carcinoma: "a cancer that starts in the milk passages (ducts) of the
breast and then breaks through the duct wall, where it grows into the fatty tissue of the
breast. at this point, it can spread elsewhere. It is the most common type of breast cancer,
accounting for about 80% of all invasive breast cancers" (American Cancer Society,
2014).
Invasive lobular carcinoma: "a cancer that starts in the milk-producing glands
(lobules) of the breast and then breaks through the lobule walls and grows into the nearby
fatty tissue. From there, it may spread elsewhere. About 1 in 10 invasive breast cancers
are invasive lobular carcinomas. This type of cancer can be hard to detect by
mammogram" (American Cancer Society, 2014).
Mammogram: "an x-ray of the breast; a method of finding breast cancer that can't
be felt using the fingers" (American Cancer Society, 2014).
Mastectomy: "surgery to remove all or part of the breast and sometimes other
tissue" (American Cancer Society, 2014).
Papilloma: "benign growth that extends out from a surface, such as wart"
(American Cancer Society, 2014).
Prophylactic mastectomy: "is a mastectomy done before any evidence of cancer
can be found, for the purpose of preventing cancer" (American Cancer Society, 2014).
Margin: "in cancer surgery or biopsy, the tissue beyond the visible edge of the
tumor or abnormal tissue that is removed along with the tumor or abnormality, in an
effort to get all of the cancer" (American Cancer Society, 2014).
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Assumptions
This study helped identify the factors as well as the influence partner, physician,
and media on the decision-making process of women with unilateral breast cancer to
undergo a CPM. The following were the assumptions that were considered:


The concern about breast cancer recurrence is one of the main factors that are
driving the decision of women with unilateral breast cancer to undergo CPM.



Surgeons could be influencing women with unilateral breast cancer to undergo
CPM.



Partners could be influencing women with unilateral breast cancer to undergo
CPM.



The media could influence women with unilateral breast cancer to make this
drastic surgical decision to undergo CPM.
Because I used a survey to conduct my research study, I assumed that the patients

would answer the questions truthfully. The consent that patients signed before answering
the survey questions assured them that their anonymity and confidentiality was preserved
and that they can withdraw from the study at any time with no ramifications. I also
assumed that the sample that I chose was representative of the population I wanted to
make inferences about. The assumption was the research provided a basis in order to
develop theories as well as research instruments.
Scope and Delimitations
The women for the research study were identified from an existing cohort of
breast cancer patients’ age 20-60 years old, who were diagnosed with unilateral breast
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cancer stage 0 to III, who had no clinical or radiographic evidence of contralateral breast
cancer, and who underwent CPM between January of 2010 and December of 2017 at MD
Anderson Cancer Center. Women who had bilateral breast cancer before undergoing
CPM, received any treatment for breast cancer before their initial visit to MD Anderson,
bilateral breast cancer before undergoing CPM, and patients with incomplete
documentation of diagnosis of breast cancer, hormone receptor status or metastatic
disease were excluded from the study. Based on the survey answers, I was able to
identify who influenced the women to make their decision to undergo CPM and their
satisfaction with their decision. Age diversity among participants created a better
understanding of the different age group decision making process. The purpose of the
time frame between January of 2010 and December of 2017 was to give time to the
participants to cope with their decision-making process and have a clearer and unbiased
answer to the survey questions. The results of my study may be valuable to other breast
cancer treatment institutions with respect to their recommendations on the use of CPM
for their own patients that are diagnosed with unilateral breast cancer. The shared model
of decision making can be used in this kind of study since it is the derivative of the
normative decision theory. The theory integrates the feature that patients are consumers
of medical care and have the right to actively participate in the decision-making process
concerning treatment choices and risk reduction strategies. I used the normative model
because it helps in breaking complex problems down into component parts, which
reduces the cognitive workloads; and link choices to norms external to decision problems
in order to ensure rational choices (Brennan, 1995). The normative decision theory
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helped promote patient satisfaction in three major ways: (a) it provided structures that
helped patients understand and clarify decision problems and make choices based on their
rationales and personal values; (b) it also helped providers to explicitly consider the
patients' values and preferences in the process of making treatment recommendations,
which increased the likelihood of the patient satisfaction with the treatment or plan of
care; and (c) it supported the implementation of guidelines thank blended the multiple
dimensions of patient satisfaction into a single, integrated judgment (Brennan, 1995).
Limitations
One possible limitation to my study was that the patients that were evaluated for
my study are inherent to one single institution, which might affect the external validity or
the generalizability of the study findings. The response bias might be the only bias that
might affect my research; the breast cancer patients can consciously or unconsciously
give responses that they think that the person conducting the research might want to see.
The major methodological strength of this study was that all women who met criteria for
the study received an e-mail to complete the survey; a larger sample size could lead to
more reliable results. In order to address the response bias limitation, clear language was
used in the survey to avoid a need for clarification to certain questions. The questions’
words and phrases were chosen with care and the questions were not framed in a way that
I would most likely get the answer I wanted to hear. Also, the amount of options were not
confusing and I communicated why and how I was conducting this survey in the
introduction part of the survey.
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Significance
There are several factors that can affect the decision-making process of women
with unilateral breast cancer to undergo a CPM. Some of the major factors are women
younger than 50 years old, being White, a family history of breast cancer, BRCA1 and
BRCA2 mutation testing, and the use of reconstruction as well as the genetic testing (Yi
et al., 2010). Breast cancer patients should understand both the benefits and risks of CPM
in order to make informed decisions. The patient decision should be influenced by
knowledge; both their own and the information provided by their oncologist. Tutle et al.
(2007) discussed the controversy of whether a physician should initiate a discussion
about CPM when a patient could be treated with lumpectomy or unilateral mastectomy.
Breast cancer patients can experience much stress around the time they are first
diagnosed and may need to decide in a very short period of time; this decision about
double mastectomy is irreversible (Tutle et al., 2007). Breast cancer patients should have
more information about their disease and the treatment options and should be more
involved in decisions about their care. Physicians should incorporate patient's values in
the treatment decision. Patients may wish to undergo a process of shared decision-making
with their provider to reach a final decision (Elwyn et al., 2012).
The purpose of this study was to assess the influence of the partner, physician,
and media on the decision of women with unilateral breast cancer who decided to
undergo CPM. The potential contribution of the study, to advance practice and promote
positive social change, was that it could help in assessing the influence of the partner,
physician, and media on the decision of women with unilateral breast cancer who decided
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to undergo CPM. The findings could highlight the need of decision aids programs or
tools that help breast cancer women increase their knowledge of their treatment options,
reduce their decisional conflicts, and make informed decisions that align with their goals
and values.
It is important for women with unilateral breast cancer to fully understand the
benefits versus the adverse effects of CPM and make an informed decision regarding the
irreversible surgical procedure. The starting point is the focus on improving the informed
decision-making process (Rosenberg, & Partridge, 2014). Evidence-driven models are
needed to better inform women about their risk of contralateral breast cancer in order to
empower them in their active decision-making process (Yi et al., 2009).
Summary
Even though the CPM can be efficacious, the decision of a woman with unilateral
breast cancer to undergo this irreversible procedure is substantial and requires that the
patient weigh the risks and the benefits with their individual values before they make
their final decision. The woman's role in the decision-making process to undergo CPM is
still unclear. Information from this study may help in assessing the influence of the
partner, physician, and media on the decision of women with unilateral breast cancer who
decided to undergo CPM. Chapter 2 will discuss the current literature, literature search
strategies, the theoretical framework, and critically evaluate the different studies that
have been conducted and focused on CPM.
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Chapter 2: Literature Review
Contralateral Prophylactic Mastectomy (CPM) is a procedure that women with
unilateral breast cancer may choose because they believe it might prevent breast cancer in
the healthy breast. The trend of the increasing rate of CPM among women with unilateral
breast cancer has raised concern, particularly with the lack of evidence for a survival
benefit related to the CPM procedure (Tracy, Rosenberg, Dominici, & Partridge, 2013),
and with the minimal (0.5%-0.75%) annual risk of women with early stage sporadic
breast cancer for developing contralateral breast cancer (Brewster & Parker, 2011).
Women might be choosing this procedure to ease their fear of recurrence, and by
believing that CPM may improve their quality of life; others might be influenced by their
physicians, partners, or even the media. Despite knowing that CPM does not improve
survival rate, many women with unilateral breast cancer are choosing this procedure in
order to ease their fear and potentially extend their lives (Rosenberg et al., 2013). There
are various reasons for the increase in CPM rates, but few studies have examined the
influence of partner, physician, as well as the media, on the women's decision-making
process. The purpose of this study was to identify the factors that affect the decisionmaking process of women who underwent CPM; and to what extent the decision, of a
woman with unilateral breast cancer to have CPM was influenced by the partner,
physician, and media. This chapter will include a discussion of the current literature,
literature search strategies, the theoretical framework, and critically evaluate the different
studies that have been conducted and focused on CPM.
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Literature Search Strategy
I performed literature searches within several databases including PubMed,
ACSO, NCBIMA, and ProQuest, as well as within online dissertations available at
Walden University. Keyword combinations included: prophylactic mastectomy, breast
cancer screening, risk factors, risk reduction, decision making, surveillance, genetic
testing, BRCA, and quality of life. Thirty three articles that pertained to breast cancer and
prophylactic mastectomies had distinctive gaps in the amount of information related to
the influence of partner, physician, and media on the decision-making process of women
with unilateral breast cancer who decided to undergo a high risk, irreversible prophylactic
mastectomy in the healthy breast. For each journal article, a review of the abstracts was
performed first, before a full-text study was reviewed. Several criteria were developed in
order to narrow the focus of the search due to the availability of hundreds of studies
related to prophylactic mastectomy. Studies were prioritized by eliminating studies that
were performed before 2007. The articles that were not peer- reviewed were also
eliminated, as well as the studies in which women were diagnosed with stage IV breast
cancer and/or had clinical or radiographic evidence of contralateral breast cancer. Articles
that involved women diagnosed with unilateral breast cancer stage 0 to III, who had no
clinical or radiographic evidence of contralateral breast cancer, were given special
attention.

22
Theoretical Foundation
Decision Science and Normative Decision Theory
Decision science claims its roots in economics, psychology, mathematics, and
probability (Brennan, 1995). There are two recognized divisions of the decision theory:
behavioral and normative (Brennan, 1995). Behavioral decision theory confirms that
when the human’s information-processing skills face a complex task, it will deteriorate,
especially when judging uncertain situations (Brennan, 1995). The normative decision
theory proposes ways "to compensate for the limitations of human information
processing" (Brennan, 1995, p. 252). The normative models help in breaking complex
problems down into component parts, which reduces the cognitive workloads and links
choices "to norms external to decision problems" (Brennan, 1995, p. 252) in order to
ensure rational choices. The normative decision theory helps promote patient satisfaction
in major ways. First, it provides structures that help patients understand and clarify
decision problems and make choices based on their rationales and personal values.
Second, it can also help providers to explicitly consider patient values and preferences in
the process of making treatment recommendations, which could increase patient
satisfaction with the treatment or plan of care and support the implementation of
guidelines that blend the multiple dimensions of patient satisfaction into a single,
integrated judgment (Brennan, 1995).
Normative decision theory suggests that an individual’s decision is made by
unbiased, logical and measured assessment of the advantages and disadvantages
surrounding a choice. Specifying criteria or evaluating standards for decision making is
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what constitute a good decision (Patel et al., 2002). Rationale decision-making is the
framing assumption of the normative decision (Patel et al., 2002). The normative models
of the physician-patient relationship in the treatment decision-making process have been
used, developed and advocated in several studies (Szasz & Hollander, 1956; Veatch,
1972; Quill, 1983; Emanuel & Emanuel, 1992; Deber, 1994).
Shared Model of Decision Making
The shared model of decision making is a derivative of the normative decision
theory and was used in my research study as a theoretical framework. It integrates the
feature that patients are consumers of medical care and have the right to actively
participate in the decision-making process concerning treatment choices and risk
reduction strategies. The normative decision theory includes an active attempt in order to
engage patient values in the decision-making process. In order to accomplish this goal,
patients are provided with decision aids such as informative brochures, videos, computer
programs, as well as physicians’ inputs. This model is conceptualized as providing the
patient with both objective medical information incorporated with subjective values and
opinions (Elwyn et al., 2012). The term shared decision making (SDM) was first
introduced in a report entitled “President’s Commission for The Study of Ethical
Problems in Medicine and Biomedical Research" (AHRQ, 1998). This report focused on
increasing interest in patient-centredness and on increasing the patient's autonomy in
healthcare interaction since 1970s (AHRQ, 1998). Referring to a Consumer Bill of
Rights, this report stated:
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Consumers have the right and responsibility to fully participate in all decisions
related to their health care. Consumers who are unable to fully participate in
treatment decisions have the right to be represented by parents, guardians, family
members, or other conservators. Physicians and other health professionals should:
provide patients with sufficient information and opportunity to decide among
treatment options consistent with the informed consent process; discuss all
treatment options with a patient in a culturally competent manner, including the
option of no treatment at all; ensure that persons with disabilities have effective
communications with members of the health system in making such decisions;
discuss all current treatments a consumer may be undergoing; discuss all risks,
benefits, and consequences to treatment or non-treatment; give patients the
opportunity to refuse treatment and to express preferences about future treatment
decisions; discuss the use of advance directives -- both living wills and durable
powers of attorney for health care -- with patients and their designated family
members; abide by the decisions made by their patients and/or their designated
representatives consistent with the informed consent process. Health plans,
providers, and facilities should: disclose to consumers factors -- such as methods
of compensation, ownership of or interest in health care facilities, or matters of
conscience -- that could influence advice or treatment decisions; assure that
provider contracts do not contain any so-called "gag clauses" or other contractual
mechanisms that restrict health care providers' ability to communicate with and
advise patients about medically necessary treatment options; be prohibited from
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penalizing or seeking retribution against health care professionals or other health
workers for advocating on behalf of their patients (AHRQ, 1998, p.1).
Achieving SDM depends on building a good relationship between the physician
and the patients in the clinical encounter in order for the information to be shared with the
breast cancer patients and that the patients are supported to express and deliberate their
preferences regarding their treatment options during the decision making process (Elwyn
et al., 2012). The patient’s decision should not only be influenced by a partner, physician,
or the media. It should play an active role in making an informed decision regarding the
treatment options. (SDM) has been defined as an approach in which physicians and
patients jointly decide which medical treatment option is best based on current evidence
and patient’s preferences, needs and values (Elwyn et al., 2012). Patients' decision can be
compromised and affected by the disease or the stressful situations, such as the new
diagnosis of breast cancer. For this reason, patients should be provided with tools and
education that help them make an informed decision.
Breast Cancer
Risk Factors
Breast cancer is a disease that affects one in eight women during their lifetime
(NIH, 2013a). It is the second leading cause of death in women after lung cancer (NIH,
2013a). It is not well understood why some women are affected with breast cancer more
than others, but there are some risk factors that could be the cause of breast cancer. Some
of these risk factors include age, genes (BRAC1 and BRAC2), personal factors, such as
women who begin their menstrual cycle before the age of 12 or go through menopause
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after age 55, being overweight, hormone replacement therapy, birth control pills,
consuming high amount of alcohol, not having the first child before the age of 35, or
having dense breasts (NIH, 2013a). Symptoms of breast cancer can differ from one
woman to another. These symptoms include a lump in the breast, changes in the shape
and size of the breast, and/or nipple discharge (NIH, 2013a). Breast cancer may be found
early through a self-breast exam, mammography, and/or clinical breast exam. If found
early, there is better chance for breast cancer to be successfully treated (ACS, 2014).
Treatment may consist of lumpectomy, mastectomy, chemotherapy, radiation, and/or
hormonal therapy. Women who are at a very high risk of developing breast cancer may
undergo a prophylactic mastectomy. In addition, the women who are diagnosed with
breast cancer and have high risk of developing breast cancer in the healthy breast may
consider CPM. Traditionally, CPM was performed on women with unilateral breast
cancer with mutations in the BRAC genes (Jin, 2013, p. 1548) but in recent years more
women with unilateral breast cancer who lack mutations are also undergoing CPM (Jin,
2013, p. 1548).
Breast Cancer Screening
The American Cancer Society’s recommendations regarding breast cancer
screenings are:


Women aged 40 years and older should have a mammogram yearly and
should continue to do so for as long as they are in good health (ACS, 2014).



Women in their 20s should start Breast Self-Exam (BSE). They should be
informed by their health professional regarding the benefits and limitations of
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SBE. Any changes in their breast should be reported immediately to their health
professional (ACS, 2014).


Women in their 20s and 30s should have a clinical breast exam (CBE) as part of a
periodic (regular) health exam by a health professional preferably every 3 years.
Starting at age 40, women should have a CBE by a health professional every year
(ACS, 2014).



Women who are at high risk (greater than 20% lifetime risk) for breast cancer
based on certain factors should get an MRI and a mammogram every year.
Women who are at moderate risk (15% to 20% lifetime risk) should talk to their
health professional regarding the benefits and limitations of adding MRI
screening to their yearly mammogram. Yearly MRI screening is not
recommended for women who are at a lifetime low risk (less than 15%) of
developing breast cancer (ACS, 2014). Breast Cancer Risk Factors That Cannot
Change Gender. Being a woman is one of the main risk factors for developing
breast cancer. Men can also develop breast cancer but the disease much more
common among women than men (ACS, 2014). This is due to the fact that men
have less of the female hormones, estrogen and progesterone, which can promote
the growth of breast cancer cells (ACS, 2014).



Aging. Age is another risk factor for developing breast cancer. The risk of
developing breast cancer increases as individuals get older (ACS, 2014). About 1
out of 8 invasive breast cancers are found in women younger than 45, and 2 of 3
invasive breast cancer are found in women age 55 and older (ACS, 2014).
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Genetic risk factors. Breast cancer can be hereditary; the American Cancer
Society believes that 5% to 10% of breast cancer cases are thought to be
hereditary (ACS, 2014), which is caused by inheriting gene defects/ mutations
from a parent. Inherited BRCA1 and BRCA2 are the most common cause of
hereditary breast cancer (ACS, 2014). In normal cells, BRCA1 and BRCA2 genes
prevent cancer by making proteins that help keep the cells from growing
abnormally (ACS, 2014); an inherited mutated copy of either gene from a parent,
can result in a higher risk of developing breast cancer during a lifetime. Women
who inherited these mutations are at high risk of developing breast cancer at a
younger age and these mutations more often affect both breasts than cancers not
linked to these mutations (ACS, 2014). Women with inherited BRCA1 and
BRCA2 gene mutations are also at high risk of developing other cancers, and
particularly ovarian cancer (ACS, 2014).
There are also changes in other genes that can put the women at a high risk of

developing breast cancer, these gene mutations are rare but can cause inherited breast
cancer as well (ACS, 2014). The following list defines various gene changes:


ATM: The normal function of the ATM genes is to help repair damaged DNA
(ACS, 2014); but inheriting one abnormal copy of the ATM gene can link to a
high rate of breast cancer in some families (ACS, 2014, p.3).



TP53: the role of this gene is to give instructions for making P53 protein that
helps stop the growth of abnormal cells (ACS, 2014). Inherited P53 mutations

29
cause Li-Fraumeni syndrome. People who have the Li-Fraumeni syndrome have a
higher risk of developing breast cancer as well as other types of cancer.


CHEK2: the Li-Fraumeni syndrome can also be caused by inherited CHEK2 gene
mutations, when mutated it can increase breast cancer risk about two-fold (ACS,
2014, p.3).

There are also other gene mutations like PTEN, CDH1, and STK11 that increase the risk
of developing breast cancer (ACS, 2014).
Additional Risk Factors
Beyond biological and genetic factors found to influence developing breast cancer
are other variables also have been found to resulting in enhanced risk. These factors
include family history, race and ethnic, dense breast tissue, certain benign breast
conditions, lobular carcinoma in situ (LCIS), early starting or late ending menstrual
periods, previous chest radiation in women, and diethylstilbestrol (DES) exposure. In this
section, I describe each of these factors.
Family history of breast cancer. Women that have close blood relatives who
have breast cancer are at higher risk of developing this disease (ACS, 2014). Having a
first-degree relative like mother, sister or daughter with breast cancer doubles the
woman’s risk for developing this disease (ACS, 2014) having more than one first-degree
relative with this disease can increase the woman’s risk about tree fold (ACS, 2014).
Race and ethnicity. Caucasian women are more likely to develop breast cancer
than African American women, but African American Women are more likely to die
from this disease (ACS, 2014). African American women 45 years of age and younger,
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are more prone to have breast cancer (ACS, 2014). Native American, Hispanic, and
Asian women are at lower risk of developing breast cancer.
Dense breast tissue. Several factors can affect breast density; some of these
factors are age, genetics, hormonal therapy for menopause, and menopausal status.
Women with dense breast tissues are at higher risk for developing breast cancer, when
compared to women with less dense breast (ACS, 2014).
Certain benign breast conditions. Women who are diagnosed with certain
benign breast conditions are at higher risk of developing breast cancer (ACS, 2014). The
benign breast conditions are often divided into three groups; non-proliferative lesions
(fibrosis, adenosis, non-sclerosing, mild hyperplasia, benign phyllodes tumor, single
papilloma, fat necrosis, duct ectasia, periductal fibrosis, squamous and apocrine
metaplasia, infection of the breast, and other benign tumors), proliferative lesions without
atypia (ductal hyperplasia without atypia, adenosis, papilloma, or scar), and proliferative
lesions with atypia (ductal hyperplasia (ADH), and lobular hyperplasia (ALH)) (ACS,
2014).
Lobular carcinoma in situ (LCIS). In LCIS, “cells that look like cancer cells are
growing in the lobules of the milk-producing glands of the breast, but they do not grow
through the wall of the lobules” (ACS, 2014, p.7). Women with LCIS are 7 to 11 times
more prone to develop breast cancer in either breast (ACS, 2014).
Menstrual periods. According to the American Cancer Society (2014), women
who had their first menstrual cycles before the age of 12 and/or went through menopause
after age 55 are at higher risk of developing breast cancer. The increase in risk is due to
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the fact that these women are more exposed during their lifetime to the hormones
estrogen and progesterone (ACS, 2014).
Previous chest radiation, women. Who at a younger age were treated with
radiation therapy to the chest due to another type of cancer like Hodgkin disease or nonHodgkin lymphoma, are at higher risk of developing breast cancer. The younger (during
adolescence) the woman was when she received chest radiation the higher the risk of
developing breast cancer; this is due to the fact that the breasts were still developing
(ACS, 2014). Radiation treatment after the age of 40 did not seem to increase the risk of
breast cancer (ACS, 2014).
Diethylstilbestrol (DES) exposure. DES was an estrogen-like drug that was
given to women from the 1940s through the early 1970s in order to lower their chances of
miscarriage (ACS, 2014). These women have a slightly increased risk of developing
breast cancer (ACS, 2014). In addition, women whose mothers took DES during
pregnancy have a slightly higher risk of developing breast cancer (ACS, 2014).
Prophylactic Mastectomy on the Rise for Breast Cancer.
Many women who are diagnosed with unilateral breast cancer are choosing to
undergo CPM in order to prevent breast cancer in the healthy breast. The rate of CPM in
the United States has more than doubled from 1.8% in 1998 to 4.5 % in 2003 (Tuttle et
al., 2007). The trend of increasing the rate of CPM among women with unilateral breast
cancer has raised concern, especially with the lack of evidence for a survival benefit
related to the CPM procedure (Tracy et al., 2013). Women may be choosing this
procedure in order to ease their fears of recurrence. These women may also believe that

32
CPM may improve their quality of life. Tuttle et al. (2007) noted that CPM is another
way to prevent breast cancer in the healthy breast; this procedure is on the rise, but is it
really necessary? The rationale of CPM comes from the premise that women who are
diagnosed with unilateral breast cancer have a better chance to survive the primary breast
tumor, that the treatment used for the index cancer might leave the women with unilateral
breast cancer at significant risk of developing contralateral breast cancer (CBC), and that
CBC will compromise their survival (Khan, 2011). Two different population-based
studies showed that in women first diagnosed with breast cancer before the age of 50, all
CBC occurred at the annual rate of 0.1%, and for the same age group but with HRnegative first breast tumor, the rate was 0.2% (Kurian et al., 2009; Bouchardy et al.,
2010). For women diagnosed with breast cancer after the age of 50 at first diagnosis, the
CBC rate was even lower (Kurian et al., 2009). The second study showed that the overall
rate of CBC is 0.3% per year; when the first breast tumor was HR-negative, the rate was
0.25%, whereas when the tumor was HR-positive, the rate was 0.65% (Bouchardy et al.,
2010). The data from these two studies revealed that the risk of developing CBC is
higher for women with an HR-negative first primary breast cancer. Thus, three different
studies confirmed that HR negativity still did not emerge as a selection factor for CBC
(Stucky et al., 2010; Arrington et al., 2009; King et al., 2011). Boughey et al. (2010)
found that there is a non-significant breast cancer-specific survival advantage for CPM.
The effectiveness of CPM in reducing breast cancer mortality is still unclear.
Tuttle et al. (2007) suggested that further studies are critically needed in order to evaluate
the patients’ decision-making process that is leading them to consider CPM, and to
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understand the decision-making process behind this aggressive breast cancer surgery.
Brewster and Parker (2011) also noted that the CPM rate in the U.S. among women with
unilateral invasive breast cancer increased by 150% from 1993 to 2003; patients might
overestimate the benefits of CPM and others may underestimate the severity of some of
the side effects associated with this procedure. It is important for women with unilateral
breast cancer to fully understand the benefits as well as the side effects that are associated
with CPM in order to make informed and supported decisions, based on accurate
understanding of the pros versus the cons of the procedure.
Efficacy of CPM
Prophylactic mastectomy can reduce the risk of breast cancer in women with
strong family history of breast cancer, who have a mutation in the BRCA1 gene or
BRCA2 gene, or who have other breast cancer associated mutations in other genes, such
as TP53 and PTEN (NCI, 2013b). However prophylactic mastectomy is not considered
an appropriate cancer prevention option for women who had breast cancer in one breast
but are not at the highest risk of developing cancer in the healthy breast; such women
may however consider the use of certain drugs to reduce their risk (NCI, 2013b). The risk
of developing another breast cancer in the same breast or the contralateral breast is very
small, especially if women receive adjuvant chemotherapy or hormone therapy as part of
their cancer treatment (NCI, 2013b). Despite knowing that CPM does not improve
survival rate, many women with unilateral breast cancer are choosing this procedure in
order to ease their fear and extend their lives (Rosenberg et al., 2013). Rosenberg et al.
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(2013) suggested that evidence-based decision-making interventions are needed in order
to improve risk communication.
Factors Associated with CPM Decision-Making
Yi et al. (2010) were able to identify different factors that were associated with
the decision-making process of women with unilateral breast cancer undergoing CPM.
The major factors identified were women younger than 50 years old, white ethnicity, a
family history of breast cancer, BRCA1 and BRCA2 mutation testing, and the use of
reconstruction as well as the genetic testing. Women were not always informed of their
absolute risk of developing contralateral breast cancer as well as the risk of recurrence
from the primary breast cancer; Yi et al. (2010) suggested that evidence-driven models
are needed to help women in their active decision-making process. Jones et al. (2009)
also showed that women who are choosing to have CPM were younger, more highly
educated, and more likely to have a family history of cancer (p. 2696). King et al. (2011)
tried to determine in their study whether the increased rate of CPM was related to the
recognition of risk factors for contralateral breast cancer or treatment factors related to
the index lesion. The result of their study showed that the increased use of CPM was not
associated with the increase recognition of the breast cancer patients who are at high risk
for CBC. Treatment factors such as MRI, immediate reconstruction, and unsuccessful
breast conservation attempts were associated with the increased rates of CPM (King et
al., 2011). King et al. (2011) also suggested that patient education is needed in order to
decrease the rates of unnecessary tests and optimize breast conservation.
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Physicians Influence on CPM Decision Making Process
A breast cancer diagnosis can carry with it a fear of death, depression, and severe
anxiety. The timing for these psychological factors could not be worse, as the women
who are diagnosed with breast cancer must make complicated treatment decisions and
pass through different treatment regimens. A significant number of women who are
diagnosed with breast cancer choose to undergo CPM in order to reduce the risk of
contralateral breast cancer (CBC; Yi et al., 2010). The decision-making process between
surgeons and patients is complicated (Yi et al., 2010). The patient- physician relationship
should shift from a traditional paternalistic model and in which all the decisions are made
primarily by the physician to one in which patients are informed of their health care,
risks, benefits, and treatment options and should participate in the decision-making
process (Nekhlyudov et al., 2005). This approach is also known as "informed decisionmaking". In this process the patient knows the risks, and benefits of her disease and
treatment options, and engages in the decision-making, or "shared decision making"
(Nekhlyudov et al., 2005, p.55). Patient involvement is important since the effect of the
decision may be substantial (Nekhlyudov et al., 2005). Assessing the patients for CBC
risks, tumor histology, and multicentricity are key elements in the decision-making
process. There are also other issues to consider which include reconstruction surgeries,
and the ability to achieve symmetry if a patient only considers unilateral mastectomy and
the projected oncologic outcome from the known ipsilateral breast cancer (Yi et al.,
2010).
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Katz and Morrow, in their article entitled "Contralateral Prophylactic Mastectomy
for Breast Cancer Addressing Peace of Mind" (Katz & Morrow, 2013) believed that
surgeons are not always clear about why they perform CPM for low risk women with
unilateral breast cancer, and that they are increasingly uncomfortable with performing
more extensive, irreversible surgeries that may be associated with additional morbidity
and complications. The majority of these patients are prone to overtreatment, especially
since the insurance companies cover CPM regardless of risk of secondary breast cancer,
and reinforce the notion that CPM is clinically indicated; it also facilitates the patient
self-referral to a surgeon who is willing to perform this procedure (Katz & Morrow,
2013). Katz and Morrow (2013) suggested that clinical indications for CPM are needed
before the insurance companies provide coverage to patients; by doing so, the factors that
may affect surgeons to address overtreatment will be reduced. Abbott et al. (2011)
highlighted an important issue regarding CPM in their study and suggested that early
physician counseling is needed in order to provide breast cancer patients with accurate
information regarding their true contralateral breast cancer (CBC) risk. They also noticed
that the rate of CPM is increasing; they decided to study and assess the perceptions of
CBC risk among breast cancer women and to evaluate the risk factors associated with the
risk perception. They concluded that the perceived risk of CBC was not associated with
the cancer stage, family history, age, or CPM; that women with UBC, and at time of
surgical evaluation overestimate their risk of CBC; however, this elevated risk perception
was not associated with choosing CPM (Abbott et al., 2011).
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Brewster and Parkers (2011) in their study “Current Knowledge on Contralateral
Prophylactic Mastectomy among Women with Sporadic Breast Cancer” discussed the
issue of the lack of information regarding the clinical value of CPM among breast cancer
patients with sporadic breast cancer, and acknowledged the fact that there is an increase
in the numbers of CPM in the United States among patients with unilateral invasive
breast cancer between 1993 and 2003 (150% increase). They also discussed the
conflicted evidence about whether CPM can reduce breast cancer mortality rates or
overall death. They noted that there are gaps in knowledge regarding the clinical value of
CPM including patient and physician related psychosocial factors that influence the
decision-making process of breast cancer women with sporadic breast cancer to undergo
CPM (Brewster, & Parker, 2011). NCI (2007) highlighted the importance for breast
cancer patients to be aware of the higher risk of systemic metastases from unilateral
breast cancer that exceeds the risk of contralateral breast cancer and that most patients
will not experience any survival benefits from CPM (NCI, 2007). Komen (2012)
provided information about the National Comprehensive Cancer Network (NCCN)
guidelines that are discouraging women to consider CPM to lower their incidence of
getting breast cancer in their healthy breast, and recommending that this procedure
should only take place if women are considered at high risk of breast cancer which
include patients who carry a BRAC1 or BRAC2 mutation or those with Li-Fraumeni
Syndromes (Komen, 2012).
Preventative medicine is usually encouraged by physicians and by the media but
choosing to remove both breasts in order to prevent breast cancer in the healthy breast
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seems to be growing increasingly common (Breast Cancer, 2013). There is limited data in
the literature characterizing the influence of physicians, partners, and the media on the
decision-making process of women with unilateral breast cancer to undergo CPM.
Celebrities Influence on CPM Decision Making Process
The media may use celebrities’ spokespersons in public health and marketing
industries in order to influence the public about an issue or a new product. Spokespeople
have more opportunities to influence behavior because the public is exposed more than
ever to media messages (Shimp, 2007). Media’s reports regarding celebrities’ decision
concerning the risk of developing breast cancer present bias toward CPM. This may say
breast cancer patients’ opinion about CPM, particularly when factors such as risk and
genetic are excluded (Sabel, 2016).
Summary and Conclusions
When faced with life threatening diseases like breast cancer, patients might make
uninformed decisions regarding their treatment. They might also overestimate the
benefits of CPM and others may underestimate the severity of some of the side effects
associated with this procedure. It is important for women with unilateral breast cancer to
fully understand the benefits as well as the side effects that are associated with CPM in
order to make informed and supported decisions, based on accurate understanding of the
pros versus the cons of the procedure. Decision-making surrounding early diagnosis of
breast cancer, with respect to CPM option, and by using a shared decision-making
approach, gives patients and physicians the opportunity to jointly decide which medical
treatment option is best based on current evidence and patient’s preferences, needs and
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values (Rosenberg, & Partridge, 2014). A clinical educational instrument is important to
help women with unilateral breast cancer make informed decision regarding CPM, and to
improve the quality of life of breast cancer survivors. Chapter 3 will describe the research
design, methodology, data collection, and data analysis used in the research. Studies
covered the various reasons for the increase in CPM rates, but few studies have examined
the influence of partner, physician, as well as the media, on the women's decision-making
process.
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Chapter 3: Research Method
Introduction
The purpose of this study was to determine whether the decision made by women
with unilateral breast cancer who underwent CPM was influenced by the physician,
partner, or media, or whether it was a shared and informed decision made by the patient.
This chapter describes the methods used in the proposed study in order to explore the
influences of physicians, partners, and media on the decision-making process of women
with unilateral breast cancer and who choose to undergo CPM. This chapter consists of
seven sections which include: the research design, population and sample size,
description of the study variables, instrumentation, data analysis, protection of patient
information, and dissemination findings, and concludes with a summary.
Research Design and Rationale
I used a quantitative cross-sectional survey design. The survey design provided a
description of the factors that affect a woman’s decision to undergo CPM as well as the
influence of the partner, physician, and the media, on the woman’s decision-making
process. The advantage of using a quantitative design in this research study is that the
researcher can use a survey to ask questions without revealing a point of view, which can
reduce potential bias (Creswell, 2009). A disadvantage to the quantitative design used in
this research is that I could not discover insights into the breast cancer patients' feelings
about the topic. The independent variables are the influence of partner, physician, and
media; the dependent variable is the decision to undergo CPM. Time and resource
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constraints are some of the barriers that I faced throughout my dissertation; my research
required many visits to the hospital library and the data collection office.
Methodology
Population
The women for the research study were identified from an existing cohort of
breast cancer patients, age 20-60 years old, who were diagnosed with unilateral breast
cancer stage 0 to III, who had no clinical or radiographic evidence of contralateral breast
cancer, and who underwent CPM between January of 2010 and December of 2017 at MD
Anderson Cancer Center; the overall number of women available to survey was 1341. I
excluded from the study, women who had bilateral breast cancer before undergoing
CPM, who had received any treatment for breast cancer before their initial visit to MD
Anderson, women who had bilateral breast cancer before undergoing CPM and patients
with incomplete documentation of diagnosis of breast cancer, hormone receptor status or
metastatic disease.
Sampling and Sampling Procedures
Women were selected from the surgical breast cancer database at MD Anderson
Cancer Center. The sample size was calculated by using the creative research systems. In
order to determine the sample size for the study, a power analysis was conducted to
determine what an optimal sample size was. Power refers to the probability that the test
used in the study will find a significant statistical difference when this difference exists
(UMICH, 2015) and that the null hypothesis can be rejected, when it should, thus voiding
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a type II error. Power should be 0.8 or greater (805) in order to find a statistically
significant difference when there is one (UMICH, 2015).
The alpha for the test of this model was set at 0.05. In order to achieve power of
0.80 and a medium effect size, a sample of 384 was required in order to detect differences
in the research study. The sample size was calculated by using the creative research
systems (Conservation Gateway, 2015); I used a confidence level of 95 and a confidence
interval level of 5 and got the sample size of 384.
Procedures for Recruitment, Participation, and Data Collection
Participants received a link to the survey using the Red Cap platform. The survey
took approximately 15 minutes to complete. An informed consent was included on the
first page of the survey. The survey allowed the participants for “no response “or “prefer
not to respond” as an option for every survey question. The email invitation collector
option was used as well in order to check if respondent has responded, opted out, or was
bounced from the recipient section. After 2 days, a reminder email was sent to
participants, and after 4 days, a second reminder email was sent to participants to remind
them to complete the survey. No clinical data was collected for patients who did not
consent to the survey.
Instrumentation and Operationalization of Constructs
The survey used in this research study included different sections that examined
the preferences, knowledge, decision making, and experiences of women with breast
cancer to have CPM; and in which participants had to check the one best answer to each
of the questions. The survey consisted of 16 questions that were adopted and modified
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from the "Prophylactic Mastectomy Outcomes Study Survey" (Geiger et al., 2006). The
Prophylactic Mastectomy Outcomes Study Survey has been used in multiple studies
(Nekhlyodov et al., 2005; Greene et al., 2006; Geiger et al., 2006a; Geiger et al., 2006b).
The development of the original survey used in these studies listed above included expert
and focus group review for validity and reliability (Nekhlyodov et al., 2005). "The
instrument included the following domains: women’s roles in the CPM decision, past and
current satisfaction with CPM, current concern about getting breast cancer again, and
depressive symptoms, as well as patient characteristics including age, race/ethnicity,
education, marital status, breast cancer stage at CPM, and current perception of general
health" (Nekhlyodov et al., 2005).
I used the modified Control Preference Scale in order to assess the women's
decision-making process at the time of CPM. The modified Control Preference Scale
was developed based on a grounded theory of how patients with life- threatening diseases
make their decisions (Nekhlyudov et al., 2005).The scale had been previously validated
to assess preferences for as well as the experiences in the decision making process, and
was modified for the use in mailed and/or telephone-administered surveys (Nekhlyudov
et al., 2005). The scale assesses patient involvement in decision making. Informed
choice is where the patients seeks information and plays an active role in the decisionmaking process. SDM is where the patient and the provider exchange information and
preferences and make joint decision. The paternalistic approach is where the patient takes
a passive role and the decision is made by the provider (Nekhlyudov et al., 2005). I also
included when a decision is made by the partner or influenced by the media to fall under
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the paternalistic approach. In order to measure between the dependent variable (decision
making) and the independent variables (influence of partner, physician, and media on the
decision making process of women with early stage unilateral breast cancer); the
participants were asked to describe their decision about the CPM and were asked to
choose all that applied from the following list:


I made the final decision to have surgery.



I made the final decision to have surgery after seriously considering my doctor's
opinion.



My doctor and I shared responsibility for the final decision to have surgery.



My doctor made the final decision about my surgery, but seriously considered my
opinion.



My doctor made the final decision about my surgery.



I made the final decision to have surgery after seriously considering my partner's
opinion.



My partner made the final decision about my surgery.

Regarding the media influence; patients were asked to choose a number to indicate
whether or not the media had influenced their decision making to undergo CPM with
number one being not at all to number five being very much. Table 1 depicts the variable
names and types that were used in this study.
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Table 1
Variables Names and Types
Variables
Partner's
Influence on
the decisionmaking process

Type of variables
Nominal

Physicians'
influence on the
decisionmaking process

Nominal

Media's
Influence on
the decisionmaking process

Ordinal

Research Questions
To what extent is the
decision, of a woman with
unilateral breast cancer, to
have CPM influenced by
partners?

To what extent is the
decision, of a woman with
unilateral breast cancer, to
have CPM influenced by
physicians?

Please choose one number
to indicate whether or not
the media had influenced
the decision of woman with
unilateral breast cancer to
undergo prophylactic
mastectomy.

Responses available
1) the woman made the
decision On Own,
2) the woman made the
decision after considering
the partner's opinion,
3) the woman shared the
decision with the partner,
and
4) the partner/doctor
decided On Own.
1) the woman made the
decision On Own,
2) the woman made the
decision after considering
the doctor’s opinion,
3) the woman shared the
decision with the doctor,
and
4) the doctor decided On
Own.
1) Not at All,
2) A Little Bit,
3) Somewhat,
4) Quite a Bit,
5) Very Much

Data Analysis
In order to assess the influence of doctors, partners, or media on patients’ decision
to have a CPM performed, four binary outcome variables were defined: Doctorinfluenced versus self-choice [implying that the patient had checked at least one of the
“doctor” related influence statements on the survey (doctor-influenced) versus having
checked the “I made the final decision to have surgery” but none of the doctor-influenced
statements (self-choice)], Partner-influenced versus self-choice [implying that the patient
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had checked at least one of the “partner” related influence statements on the survey
(partner-influenced) versus having checked the “I made the final decision to have
surgery” but none of the partner-influenced statements (self-choice), for patients who
indicated the presence of partners under the Marital Status section of the survey], Mediainfluenced versus self-choice [implying that the patient had checked at least one of the
“media” related influence statements on the survey other than “Not At All” (mediainfluenced) versus having checked the “I made the final decision to have surgery” but
none of the media-influenced statements (self-choice)], Any-influence versus self-choice
[implying that the patient had checked at least one of the doctor, partner, or media related
influence statements on the survey as with the above variables]. Henceforth these binary
variables will be referred to as simply doctor-influenced, partner-influenced, mediainfluenced, and any-influenced.
Incidence of each of the binary outcomes was modeled by logistic regression
(binomial distribution with logit link). For each outcome, inclusion of potential
covariates was assessed by adding them to the model and comparing them to the model
without the covariate based upon the Akaike Information Criteria (AIC); models
including a covariate which did not improve (lower) the AIC with relation to the model
without it implicitly show no evidence of significant association between the outcome
and that covariate. Potential covariates considered included the presence of family
history of breast cancer, age category, race, marital status, presence of partner, education
category, presence of estrogen or progesterone receptor, presence of lymphovascular
invasion (LVI), whether the CPM was performed on a different versus the same day as
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the definitive surgery, tumor grade, and pathology stage. For the doctor-influenced and
partner-influenced models, only the inclusion of the covariate for family history of breast
cancer improved the model. For the media influenced model, none of the covariates
yielded improved models over the intercept-only model. For the any-influence model,
inclusion of the covariates for family history of breast cancer and pathology stage each
improved the model and including both covariates yielded the most improved model.
Further, inclusion of both of these variables in models for the other outcomes had little
effect on the otherwise optimal model, so for consistency I will base final analysis
summaries and figures on these two-covariate models. Note that the covariates for
marital status and presence of partner were excluded from consideration of inclusion in
the partner-influenced and any-influenced model due to confounding with partnerinfluence. Differences among levels of variables with 3 or more levels were assessed by
Tukey-adjusted contrasts.
Additionally, for the sake of completion, fully-adjusted versions of the above
models for each of the binary outcomes were produced, including the presence of
covariates for family history of breast cancer, age category, race, presence of partner,
education category, presence of estrogen or progesterone receptor, presence of
lymphovascular invasion (LVI), whether the CPM was performed on a different versus
the same day as the definitive surgery, tumor grade, and pathology stage, with the
exception that the presence of partner was excluded from inclusion in the partnerinfluenced and any-influenced model due to confounding with partner-influence. These
fully adjusted models had by far the highest AICs among the models considered for each
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outcome, and were thus the worst among all models, plus may be subject to some lack of
independence among the covariates.
Statistical analyses were performed using R statistical software (R Core Team, 2019,
version 3.6.1). In all statistical tests, two-sided alpha=.05. Predictions and differences
among factor levels in the logistic regression models were estimated using the
“emmeans” package (Lenth 2018); this includes adjusted means weighted proportionally
to covariate marginal frequencies. Catseye plots (Cumming 2014) were produced using
the “catseyes” package (Andersen 2019).
For Research Question 1 (Quantitative): To what extent is the decision, of a
woman with unilateral breast cancer, to have CPM influenced by partners?
Potential covariates considered included the presence of family history of breast cancer,
age category, race, education category, presence of estrogen or progesterone receptor,
presence of lymphovascular invasion (LVI), whether the CPM was performed on a
different versus the same day as the definitive surgery, tumor grade, and pathology stage.
For partner-influenced models, only the inclusion of the covariate for family history of
breast cancer improved the model (p=0.014).
For Research Question 2 (Quantitative): To what extent is the decision, of a
woman with unilateral breast cancer, to have CPM influenced by physicians?
Potential covariates considered included the presence of family history of breast cancer,
age category, race, presence of partner, education category, presence of estrogen or
progesterone receptor, presence of lymphovascular invasion (LVI), whether the CPM was
performed on a different versus the same day as the definitive surgery, tumor grade, and
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pathology stage. For the doctor-influenced models, only the inclusion of the covariate for
family history of breast cancer improved the model (p=0.041).
For Research Question 3 (Quantitative): To what extent is the decision, of a
woman with unilateral breast cancer, to have CPM influenced by the media?
Potential covariates considered included the presence of family history of breast cancer,
age category, race, presence of partner, education category, presence of estrogen or
progesterone receptor, presence of lymphovascular invasion (LVI), whether the CPM was
performed on a different versus the same day as the definitive surgery, tumor grade, and
pathology stage. For the media-influenced models, only the inclusion of the covariate for
pathological stage (II-0) improved the model (p=0.022).
The research questions that guided this study were:
The research questions and hypotheses for this study were as follows:
Research Question 1: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by partners?
H01: Partners have no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
H11: Partners have a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
Research Question 2: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by physicians?
H02: Physicians have no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
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H12: Physicians have a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
Research Question 3: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by the media?
H03: The media has no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
H13: The media has a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
The independent variables were the influence of partner, physician, and media;
the dependent variable was the decision to undergo CPM. The woman’s decision-making
roles regarding CPM were divided into five categories: (a) the woman made the decision
on her own, (b) the woman’s decision to undergo CPM was influenced by the physician,
(c) the woman shared the decision with her physician, (d) the woman’s decision to
undergo CPM was influenced by the partner, and (e) the woman’s decision to undergo
CPM was influenced by the media. Potential covariates considered included the presence
of family history of breast cancer, age category, race, presence of partner, education
category, presence of estrogen or progesterone receptor, presence of lymphovascular
invasion (LVI), whether the CPM was performed on a different versus the same day as
the definitive surgery, tumor grade, and pathology stage.
Threats to Validity
Experimental mortality and internal validity: there are several reasons why some
patients might drop out of the research study. Some of these reasons are: death, no longer
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willing to participate in the study, no longer available, and geographical move. The
experimental mortality becomes a threat to internal validity when the number of dropouts
is large, which can affect the sample size of the research study. Also, any factor that can
affect the generalizability of the results will have a threat to external validity. Selection
bias might be one of the factors that can have a threat to external validity since I was
chose all the participants from only one cancer organization. When selection bias occurs,
it is difficult to argue that the result might not be generalized to the wider population.
Random irrelevancies in the experimental setting is a threat to the statistical conclusion
validity since the patients that are answering the survey questions in this specific cancer
facility might have a different experience than patients in different settings/facilities.
Ethical Procedures
MD Anderson, Breast Oncology Research department was contacted regarding the
study. MD Anderson Institutional Review Board (IRB# PA18-0378) is the IRB of record for
the research study and permission was obtained to contact the patients that meet the inclusion
criteria of the study via e-mail. An informed consent was included on the first page of the
survey. Since I emailed the survey questions using the Red Cap to participants, issues

such as privacy can become a threat because of the use of the internet/ computer-based
method to answer the survey questions. The use of technology might inappropriately
limit the sample. Also, for patients who have had a mastectomy, completing a survey
about their experience could trigger some unpleasant memories. Participants were
reminded on the survey that their participation was voluntary. Patient’s confidentiality
was assured. The information gathered by each individual patient was used as part of a
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larger statistical analysis. Patients were not harmed because data from individual patients
were de-identified. Participants’ data were stored in the principal investigator’s computer,
which was password protected. After study termination, data and identifiers were handled
per applicable institutional policies. No adverse impacts were expected on rights or
welfare of the subject because confidentiality was protected. Identifiers (name, medical
record number, email address, location) were collected but were replaced by coded study
numbers in the analytic file. Data will be destroyed after a 5-year period.
Summary
Three hundred eighty-four women with stage 0 to III early stage unilateral breast
cancer age 20-60 years old who underwent CPM at the cancer center between January of
2010 and December of 2017 were the target population for this quantitative study which
used a cross-sectional survey design. Descriptive statistics was used to analyze the
characteristics of the patients, and binary outcomes modeled by logistic regression
(binomial distribution with logit link) was used in order to assess the influence of doctors,
partners and media on patient’s decision to have CPM. For each outcome, inclusion of
potential covariates was assessed by adding them to the model and comparing them to the
model without the covariate based upon the Akaike Information Criteria (AIC); models
including a covariate which did not improve (lower) the AIC with relation to the
intercept-only model implicitly show no evidence of significant association between the
outcome and that covariate. Chapter 4 will provide a summary of the results for this
study.
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Chapter 4: Results
Introduction
The purpose of this study was to assess the influence of the physician, partner,
and media on women’s decision making with regards to the utilization of CPM among
women with early stage unilateral breast cancer and to determine to what extent their
decision was influenced by their physician, partner, and media. The research questions
and hypotheses for this study were as follows:
The research questions and hypotheses for this study were as follows:
Research Question 1: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by partners?
H01: Partners have no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
H11: Partners have a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
Research Question 2: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by physicians?
H02: Physicians have no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
H12: Physicians have a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
Research Question 3: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by the media?
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H03: The media has no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
H13: The media has a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
In Chapter 4, I describe the data collection process including the time frame, the response
rates, the discrepancies in the data collection, the characteristic of the sample, validity,
and inclusion criteria and variables. It will also discuss the challenges and the adverse
events faced during the survey process, and the results of the analysis.
Data Collection
Using the prospectively maintained Breast Cancer Database Management System
housed in the Department of Breast Medical Oncology at MDACC, I identified 1341
women with a diagnosis of early-stage (stage 0-III), breast cancer who underwent CPM
between January of 2010 and December of 2017 at MDACC with no clinical or
radiographic evidence of contralateral breast cancer. The database was developed and
maintained prospectively in line with stringent quality controls and its structure is very
similar to the national comprehensive cancer network (NCCN) database to which there
has been major contributions over the last 2 decades. To avoid selection bias, I included
those who had received their initial treatment and subsequent surveillance visits at
MDACC and excluded those who had presented only for an initial consultation or a
second opinion (see Sinha et al., 2017). I reviewed the electronic medical records of
these women and extracted data on demographic characteristics, including ethnicity/race,
family history of breast in first- and second-degree relatives, BRCA status, tumor
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characteristics, including tumor stage, biomarkers and grade and treatment received (type
of surgery, radiotherapy, and endocrine therapy). Patients self-reported their race at the
time of registration. Following the inclusion criteria, all the patients were aged 20 to 60
years at diagnosis. I excluded patients who had received any treatment for breast cancer
before their initial visit to MD Anderson, women who had bilateral breast cancer before
undergoing CPM and patients with incomplete documentation of diagnosis of breast
cancer, hormone receptor status or metastatic disease. Also excluded were individuals
incapable or unwilling to sign the informed consent.
The tumor stage was determined using the seventh edition of the American Joint
Committee on Cancer guidelines (Edge & Compton, 2010). Biomarkers of tumors were
those that were either estrogen receptor positive or negative (ER + or ER-) or
progesterone receptor positive or negative (PR + or PR -) as determined by
immunohistochemistry using institutional cutoffs. Human epidermal receptor (HER2)
status was assessed by immunohistochemistry or fluorescence in situ hybridization when
available and determined as positive or negative on the basis of institutional cutoffs and
guidelines that were current at the time of diagnosis (Wolff et al., 2013).
This study was conducted under MD Anderson Institutional Review Board
(#PA18-0378), and an informed consent was obtained from all participants. All the
women who met the criteria of the sampling from the database at the Cancer Center were
asked to complete the survey. The survey included different sections that examined the
preferences, knowledge, decision making, and experiences of women with breast cancer
to have CPM. Participants had to check the one best answer to each of the questions. The
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survey consisted of 16 questions that were adopted and modified from the "Prophylactic
Mastectomy Outcomes Study Survey." The instrument includes the following domains:
women’s roles in the CPM decision, satisfaction with CPM, current concern about getting
breast cancer again, and depressive symptoms, as well as patient characteristics including
age, race/ethnicity, education, marital status, breast cancer stage at CPM, and current
perception of general health" (Geiger et al., 2006).
Survey data were collected and managed using REDCap electronic data capture
tools hosted at MD Anderson cancer center (Harris et al., 2009). REDCap (Research
Electronic Data Capture) is a secure, web-based application designed to support data
capture for research studies, providing: 1) an intuitive interface for validated data entry;
2) audit trails for tracking data manipulation and export procedures; 3) automated export
procedures for seamless data downloads to common statistical packages; and 4)
procedures for importing data from external sources.
Results
Descriptive Statistics
Descriptive statistics were performed on the women who were enrolled in the
study. Following are the results of the analysis related to age, race, education, and marital
status.
Table 2 illustrates the results of the descriptive analysis related to age.
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Table 2
Age of women who underwent CPM

Age Group

Counts

Frequency

20 to 30

10

2.80%

31 to 40

91

25.20%

41 to 50

161

44.60%

51 to 60

99

27.40%

Total

361

100%

Table 3 illustrates the results of the descriptive analysis related to Race.
Table 3
Race of women who underwent CPM

Age Group

Counts

Frequency

Asian or Pacific Islander

13

3.6%

Black or African American

15

4.2%

Hispanic, Latino

40

11.1%

3

0.8%

285

78.9%

Other

5

1.4%

Total

361

Native American or Alaskan
White or Caucasian

100%
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Table 4 illustrates the results of the descriptive analysis related to the level of education.
Table 4
Highest level of education of women who underwent CPM

Education Level
Less than or some high school

Counts
0

Frequency
0%

High school or GED

29

8.1%

Trade or technical school

13

3.6%

Junior college or some college

64

17.9%

College graduate

132

36.9%

Post graduate work or degree

120

33.5%

Total

358

100%

Table 5 illustrates the results of the frequency analysis related to the marital status.
Table 5
Marital status of women who underwent CPM

Marital status

Counts

Married

305

81.8%

Lived together but not married

12

3.2%

Separated or divorced

28

7.5%

Widowed

10

2.7%

Never married

18

4.8%

Total

373

Frequency

100%
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Table 6 illustrates the results of the frequency analysis related to women’s concern.
Table 6
Concern level of women who underwent CPM

Concern levels

Counts

Very concerned

135

36.4%

Concerned

73

19.7%

Not very concerned

78

21.0%

Not concerned at all

85

22.9%

Total

371

Frequency

100%

Three research questions guided this study:
The research questions and hypotheses for this study were as follows:
Research Question 1: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by partners?
H01: Partners have no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
H11: Partners have a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
Research Question 2: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by physicians?
H02: Physicians have no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
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H12: Physicians have a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
Research Question 3: To what extent is the decision of a woman with unilateral
breast cancer to have CPM influenced by the media?
H03: The media has no significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
H13: The media has a significant influence on the decision-making process of
women with unilateral breast cancer to undergo CPM.
.
The decision-making process and the effect of physician, partner, and media, the
percentages were calculated using the relative frequency of the responses to the questions
(n = 372). Table 7 illustrates the percentages of the relative frequency analysis related to
the decision-making process and the effect of physician, partner, and media, on the
decision-making process of women who underwent CPM.

61
Table 7
Decision-making process and the effect of physician, partner and media of women who underwent CPM
Decision
Counts
Frequency
I made the final decision to have surgery

201

54%

I made the final decision to have surgery after seriously considering my

165

44.4%

60

16.1%

2

0.5%

4

1.1%

59

15.9%

1

0.3%

373

100%

doctor's opinion.
My doctor and I shared responsibility for the final decision to have surgery.
My doctor made the final decision about my surgery, but seriously considered
my opinion.
My doctor made the final decision about my surgery.
I made the final decision to have surgery after seriously considering my
partner's opinion.
My partner made the final decision about my surgery.
Total
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The probability of doctor-influenced CPM decision per logistic regression is
illustrated in figure 1; the overall probability is shown at left, followed by separate
probabilities based upon family history of breast cancer at right. The distribution of the
model-adjusted means is illustrated by catseye plots with shaded +/- standard error and
have been transformed from the logit scale to the probability scale such that distributions
near 0% or 100% are asymmetrically distorted accordingly.

Figure 1. Probability of Doctor-Influenced CPM Decision per Logistic Regression

The probability of partner-influenced CPM decision per logistic regression is illustrated
in figure 2. The overall probability is shown at left, followed by separate probabilities
based upon family history of breast cancer at right. The distribution of the modeladjusted means is illustrated by catseye plots with shaded +/- standard error and have
been transformed from the logit scale to the probability scale such that distributions near
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0% or 100% are asymmetrically distorted accordingly. The shaded horizontal line
indicates 50% probability.

Figure 2. Probability of Partner-Influenced CPM Decision per Logistic Regression

The probability of media-influenced CPM decision per logistic regression is illustrated in
figure 3. The distribution of the model-adjusted mean is illustrated by catseye plot with
shaded +/- standard error and has been transformed from the logit scale to the probability
scale such that distributions near 0% or 100% are asymmetrically distorted accordingly.
The shaded horizontal line indicates 50% probability
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Figure 3. Probability of Media-Influenced CPM Decision per Logistic Regression.

The probability of any influenced CPM decision per logistic regression is illustrated in
figure 4. The overall probability is shown at left, followed by separate probabilities based
upon family history of breast cancer at right. The distribution of the model-adjusted
means is illustrated by catseye plots with shaded +/- standard error and have been
transformed from the logit scale to the probability scale such that distributions near 0% or
100% are asymmetrically distorted accordingly. The shaded horizontal line indicates
50% probability.
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Figure 4. Probability of Any-Influenced CPM Decision per Logistic Regression.
In order to assess the influence of doctors, partners, or media on patients’ decision
to have a CPM performed, four binary outcome variables were defined: Doctorinfluenced versus self-choice [implying that the patient had checked at least one of the
“doctor” related influence statements on the survey (doctor-influenced) versus having
checked the “I made the final decision to have surgery” but none of the doctor-influenced
statements (self-choice)]; Partner-influenced versus self-choice [implying that the patient
had checked at least one of the “partner” related influence statements on the survey
(partner-influenced) versus having checked the “I made the final decision to have
surgery” but none of the partner-influenced statements (self-choice), for patients who
indicated the presence of partners under the Marital Status section of the survey]; Mediainfluenced versus self-choice [implying that the patient had checked at least one of the
“media” related influence statements on the survey other than “Not At All” (mediainfluenced) versus having checked the “I made the final decision to have surgery” but
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none of the media-influenced statements (self-choice)]; Any-influence versus self-choice
[implying that the patient had checked at least one of the doctor, partner, or media related
influence statements on the survey as with the above variables]. Henceforth these binary
variables will be referred to as simply doctor-influenced, partner-influenced, mediainfluenced, and any-influenced.
Incidence of each of the binary outcomes was modeled by logistic regression
(binomial distribution with logit link). For each outcome, inclusion of potential
covariates was assessed by adding them to the model and comparing them to the model
without the covariate based upon the Akaike Information Criteria (AIC); models
including a covariate which did not improve (lower) the AIC with relation to the model
without it implicitly show no evidence of significant association between the outcome
and that covariate. Potential covariates considered included the presence of family
history of breast cancer, age category, race, marital status, presence of partner, education
category, presence of estrogen or progesterone receptor, presence of lymphovascular
invasion (LVI), whether the CPM was performed on a different versus the same day as
the definitive surgery, tumor grade, and pathology stage. For the doctor-influenced and
partner-influenced models, only the inclusion of the covariate for family history of breast
cancer improved the model. For the media influenced model, none of the covariates
yielded improved models over the intercept-only model. For the any-influence model,
inclusion of the covariates for family history of breast cancer and pathology stage each
improved the model and including both covariates yielded the most improved model.
Further, inclusion of both of these variables in models for the other outcomes had little
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effect on the otherwise optimal model, so for consistency I will base final analysis
summaries and figures on these two-covariate models. Note that the covariates for
marital status and presence of partner were excluded from consideration of inclusion in
the partner-influenced and any-influenced model due to confounding with partnerinfluence. Differences among levels of variables with 3 or more levels were assessed by
Tukey-adjusted contrasts.
Additionally, for the sake of completion, fully-adjusted versions of the above
models for each of the binary outcomes were produced, including the presence of
covariates for family history of breast cancer, age category, race, presence of partner,
education category, presence of estrogen or progesterone receptor, presence of
lymphovascular invasion (LVI), whether the CPM was performed on a different versus
the same day as the definitive surgery, tumor grade, and pathology stage, with the
exception that the presence of partner was excluded from inclusion in the partnerinfluenced and any-influenced model due to confounding with partner-influence. These
fully adjusted models had by far the highest AICs among the models considered for each
outcome, and were thus the worst among all models, plus may be subject to some lack of
independence among the covariates.
Statistical analyses were performed using R statistical software (R Core Team,
2019, version 3.6.1). In all statistical tests, two-sided alpha=.05. Predictions and
differences among factor levels in the logistic regression models were estimated using the
“emmeans” package (Lenth 2018); this includes adjusted means weighted proportionally
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to covariate marginal frequencies. Catseye plots (Cumming 2014) were produced using
the “catseyes” package (Andersen 2019).
Overall, 203/343 patients reported some doctor influence on the CPM decision.
The logistic regression model of the incidence of doctor-influence demonstrated
significantly higher overall influence on the CPM decision due to doctors compared to
self-determination alone (p=.0006), suggesting that 59% of patients’ decisions were
influenced by doctors. The model also showed that patients with a family history of
breast cancer had significantly higher odds of doctor-influence than those without
(p=.029). There was no evidence of association with pathology stage. These results are
summarized in table 8.
Table 8
Logistic Regression Model Summary for Incidence of Doctor-Influence.

Adj.
Mean
Overall

0.38

SE
0.11

Probability CI95Min CI95Max p-value
0.59

0.54

0.65

0.0005

Overall probability of doctor Influence

Difference due to family history of breast cancer

Contrast
Estimate SE
OddsRatio CI95Min CI95Max p-value
0.50
0.23
1.64
1.05
2.57
0.029
True - False
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Difference due to pathology stage (note that these are Tukey-adjusted p –values). The overall
Type III p=0.27

Contrast Estimate SE
OddsRatio CI95Min CI95Max p-value
-0.28
0.31
0.75
0.41
1.39
0.80
I-0
II-0
II-I
III-0

-0.55

0.34

0.58

0.30

1.12

0.37

-0.26

0.27

0.77

0.45

1.31

0.77

-0.70

0.42

0.50

0.22

1.13

0.34

-0.42

0.37

0.66

0.32

1.36

0.67

-0.16

0.39

0.86

0.40

1.83

0.98

III-I
III-II
Overall, 53/189 patients with partners reported some partner influence on the
CPM decision. The logistic regression model of the incidence of partner-influence
demonstrated significantly lower overall influence on the CPM decision due to partners
compared with self-determination alone (p<.0001, same with Hommel adjustment),
suggesting that 27% of patients’ decisions were influenced by partners. The model also
showed that patients with a family history of breast cancer had significantly higher odds
of partner-influence than those without (p=.0015). There was no evidence of association
with pathology stage. These results are summarized in table 9.
Table 9
Logistic Regression Model Summary for Incidence of Partner-Influence.

Adj. SE
Mean
Overall

-.99

0.17

Probability CI95Min CI95Max p-value
0.27

0.21

0.34

<.0001

Overall probability of partner influence

Difference due to family history of breast cancer
Contrast
Estimate SE
OddsRatio CI95Min CI95Max p-value
0.81
0.33
2.25
1.17
4.34
0.015
True - False
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Difference due to pathology stage (note that these are Tukey-adjusted p –values). The overall
Type III p=0.46

Contrast Estimate SE
OddsRatio CI95Min CI95Max p-value
-0.13
0.43
0.88
0.38
2.03
0.99
I-0
II-0
II-I
III-0

-0.67

0.50

0.51

0.19

1.38

0.55

-0.54

0.44

0.58

0.25

1.38

0.61

-0.63

0.62

0.53

0.16

1.79

0.74

-0.50-

0.57

0.61

0.20

1.85

0.82

0.04

0.63

1.04

0.30

3.55

1

III-I
III-II
Overall, 36/213 patients reported some level of media influence on the CPM
decision. The logistic regression model of the incidence of media-influence
demonstrated significantly lower overall influence on the CPM decision due to media
compared with self-determination alone (p<.0001), suggesting that 16% of patients’
decisions were influenced by media. The model also showed that patients with a family
history of breast cancer trended higher in incidence of association with media influence,
but this trend lacked evidence of significance (p=.59). There was no evidence of
association with pathology stage. These results are summarized in table 10.
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Table 10
Logistic Regression Model Summary for Incidence of Media-Influence.
Adj. SE
Probability CI95Min CI95Max p-value
Mean
Overall -1.68
0.20
0.16
0.11
0.22
<.0001
Overall probability of media influence
Difference due to family history of breast cancer
Adj.
SE
OddsRatio CI95Min CI95Max p-value
Mean
Overall
0.21
0.38
1.23
0.59
2.58
<.059
Overall probability of media influence
Difference due to pathology stage (note that these are Tukey-adjusted p –values). The overall
Type III p=0.08

Contrast Estimate SE
OddsRatio CI95Min CI95Max p-value
-0.66
0.44
0.52
0.22
1.22
0.44
I-0
II-0
II-I
III-0

-1.19

0.54

0.30

0.10

0.88

0.13

-0.53

0.52

0.59

0.21

1.62

0.73

-1.54

0.81

0.21

0.04

1.05

0.23

-0.88

0.79

0.41

0.09

1.95

0.68

-0.35

0.86

0.71

0.13

3.78

0.98

III-I
III-II

Overall, 224/332 patients reported some level of any influence on the CPM
decision. The logistic regression model of the incidence of any-influence demonstrated
significantly higher overall influence on the CPM decision due to any-influence
compared with self-determination alone (p<.0001), suggesting that 68% of patients’
decisions were influenced by some combination of doctor, partner, or media. The model
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also showed that patients with a family history of breast cancer had significantly higher
odds of any-influence than those without (p=.040). Additionally, this model showed
evidence that patients with lower pathology stage tended to have higher probability of
any-influence on their decision, and a trend of declining influence with higher stage.
These results are summarized in table 11.
Table 11
Logistic Regression Model Summary for Incidence of Any-Influence.
Adj.
SE
Probability CI95Min CI95Max p-value Hommel
Mean
p-value
.75
0.12
0.68
0.63
0.73
<.0001
<0.0001
Overall
Overall probability of any influence
Difference due to family history of breast cancer
Contrast
Estimate SE
OddsRatio CI95Min CI95Max p-value
True - False

0.50

0.24

1.64

Logistic Regression Model, with Logit Link

1.02

2.64

0.040

Hommel
p-value
0.040
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Table 12
DecisionDoctorVsSelf FamHis, Age,Race,Partner Education, Receptor,
Lymphatic_Invasion, DiffDaySurg, Tumor Grade, PathStage
Coefficients
(Intercept)

Estimate

Std. Error

p-value

-0.381

0.835

0.65

FamHist (TRUE - FALSE)

0.490

0.239

*0.041

Age (41 to 50 years old - 31 to 40 years old)

0.265

0.290

0.36

Age (20 to 30 years old - 31 to 40 years old)

0.695

0.763

0.36

Age (51 to 60 years old - 31 to 40 years old)

0.005

0.320

0.99

Race (Hispanic/Latino - White or Caucasian)

-0.577

0.381

0.13

Race (Black or African American - White or Caucasian)

-0.666

0.608

0.27

Race (Asian or Pacific Islander - White or Caucasian)

0.040

0.612

0.95

Race (Other - White or Caucasian)

0.139

0.761

0.86

Partner (TRUE - FALSE)

0.309

0.331

0.35

Education (Trade or technical school - High school or GED)

0.714

0.745

0.34

Education (Junior college, or some college - High school or
GED)

0.610

0.486

0.21

Education (College graduate - High school or GED)

0.569

0.444

0.20

Education (Postgraduate work or degree - High school or GED)

0.753

0.446

0.09

Receptor (TRUE - FALSE)

0.261

0.311

0.40

Lymphatic Invasion (POS - NEG)

0.184

0.283

0.51

DiffDaySurg (TRUE - FALSE)

-0.173

0.320

0.59

TumorGrade (II - I)

-0.270

0.500

0.59

TumorGrade (III - I)

0.017

0.513

0.97

PathStage (I - 0)

-0.417

0.347

0.23

PathStage (II - 0)

-0.742

0.381

0.052

PathStage (III - 0)

-0.807

0.486

0.10
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Table 13
DecisionPartnerVsSelf FamHis, Age,Race, Education, Receptor, Lymphatic_Invasion,
DiffDaySurg, Tumor Grade, PathStage
Coefficients
(Intercept)

Estimate

Std.
Error

pvalue

-0.595

1.182

0.61

0.884

0.359

*0.014

Age (41 to 50 years old - 31 to 40 years old)

-0.345

0.431

0.42

Age (20 to 30 years old - 31 to 40 years old)

0.335

1.351

0.80

Age (51 to 60 years old - 31 to 40 years old)

-0.370

0.480

0.44

Race (Hispanic/Latino - White or Caucasian)

-0.122

0.558

0.83

Race (Black or African American - White or Caucasian)

0.388

0.937

0.68

Race (Asian or Pacific Islander - White or Caucasian)

0.327

0.816

0.69

-15.787

1187.688

0.99

-0.138

1.115

0.90

Education (Junior college, or some college - High school or GED)

0.559

0.752

0.46

Education (College graduate - High school or GED)

0.239

0.692

0.73

Education (Postgraduate work or degree - High school or GED)

0.235

0.711

0.74

Receptor (TRUE - FALSE)

0.145

0.451

0.75

Lymphatic Invasion (POS - NEG)

0.602

0.422

0.15

DiffDaySurg (TRUE - FALSE)

-0.623

0.512

0.22

TumorGrade (II - I)

-0.726

0.750

0.33

TumorGrade (III - I)

-0.591

0.772

0.44

PathStage (I - 0)

-0.068

0.480

0.89

PathStage (II - 0)

-0.892

0.583

0.13

PathStage (III - 0)

-0.675

0.726

0.35

FamHist (TRUE - FALSE)

Race (Other - White or Caucasian)
Education (Trade or technical school - High school or GED)
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Table 14
DecisionMediaVsSelf FamHis, Age,Race,Partner, Education, Receptor,
Lymphatic_Invasion, DiffDaySurg, Tumor Grade, PathStage
Coefficients
(Intercept)

Estimate

Std.
Error

pvalue

-0.497

1.440

0.73

0.318

0.414

0.44

Age (41 to 50 years old - 31 to 40 years old)

-0.137

0.479

0.77

Age (20 to 30 years old - 31 to 40 years old)

0.755

1.055

0.47

Age (51 to 60 years old - 31 to 40 years old)

-0.662

0.584

0.26

Race (Hispanic/Latino - White or Caucasian)

-0.374

0.690

0.59

Race (Black or African American - White or Caucasian)

1.395

0.766

0.069

Race (Asian or Pacific Islander - White or Caucasian)

0.693

0.814

0.39

-14.595

1066.555

0.99

0.311

0.642

0.63

-0.039

1.435

0.98

Education (Junior college, or some college - High school or GED)

0.845

0.943

0.37

Education (College graduate - High school or GED)

0.810

0.865

0.35

Education (Postgraduate work or degree - High school or GED)

0.500

0.885

0.57

-0.145

0.529

0.78

0.107

0.518

0.84

DiffDaySurg (TRUE - FALSE)

-0.217

0.614

0.72

TumorGrade (II - I)

-0.730

0.754

0.33

TumorGrade (III - I)

-1.521

0.819

0.063

PathStage (I - 0)

-0.824

0.528

0.12

PathStage (II - 0)

-1.552

0.675

*0.022

PathStage (III - 0)

-1.663

0.929

0.07

FamHist (TRUE - FALSE)

Race (Other - White or Caucasian)
Partner (TRUE - FALSE)
Education (Trade or technical school - High school or GED)

Receptor (TRUE - FALSE)
Lymphatic Invasion (POS - NEG)
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Table 15
DecisionAnyVsSelf FamHis, Age,Race,Partner, Education, Receptor,
Lymphatic_Invasion, DiffDaySurg, Tumor Grade, PathStage
Coefficients

Estimate

Std.
Error

pvalue

(Intercept)

0.507

0.852

0.55

FamHist (TRUE - FALSE)

0.519

0.258

*0.044

Age (41 to 50 years old - 31 to 40 years old)

0.098

0.311

0.75

Age (20 to 30 years old - 31 to 40 years old)

1.797

1.128

0.11

Age (51 to 60 years old - 31 to 40 years old)

-0.042

0.343

0.90

Race (Hispanic/Latino - White or Caucasian)

-0.403

0.414

0.33

0.163

0.722

0.82

Race (Asian or Pacific Islander - White or Caucasian)

-0.270

0.622

0.66

Race (Other - White or Caucasian)

-0.138

0.763

0.86

Education (Trade or technical school - High school or GED)

0.958

0.786

0.22

Education (Junior college, or some college - High school or
GED)

0.989

0.523

0.059

Education (College graduate - High school or GED)

0.722

0.473

0.13

Education (Postgraduate work or degree - High school or GED)

0.885

0.481

0.066

Receptor (TRUE - FALSE)

0.297

0.341

0.38

Lymphatic Invasion (POS - NEG)

0.092

0.298

0.76

DiffDaySurg (TRUE - FALSE)

-0.224

0.334

0.50

TumorGrade (II - I)

-0.063

0.525

0.91

TumorGrade (III - I)

0.000

0.542

1.00

PathStage (I - 0)

-0.975

0.413

*0.018

PathStage (II - 0)

-1.235

0.451

*0.006

PathStage (III - 0)

-1.545

0.536

*0.004

Race (Black or African American - White or Caucasian)
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Fully Adjusted Model: For each outcome, inclusion of potential covariates was
assessed by adding them to the model and comparing them to the model without the
covariate based upon the Akaike Information Criteria (AIC); models including a
covariate which did not improve (lower) the AIC with relation to the intercept-only
model implicitly show no evidence of significant association between the outcome and
that covariate. Potential covariates considered included the presence of family history of
breast cancer, age category, race, marital status, presence of partner, education category,
presence of estrogen or progesterone receptor, presence of lymphovascular invasion
(LVI), and whether the CPM was performed on a different versus the same day as the
definitive surgery. Except for family history of breast cancer for the doctor-influenced,
media-influenced, and any-influenced outcomes, inclusion of each of the covariates alone
or in combination with family history resulted in a worsened model (higher AIC)
compared to the intercept-only model. Note that the covariates for marital status and
presence of partner were excluded from inclusion in the partner-influenced and anyinfluenced model due to confounding with partner-influence. The results of the adjusted
models are illustrated in the tables below.
Table 16
Decision Doctor Vs Self Fully Adjusted Model Logistic Regression
for Family History
Probability CI95Min CI95Max
FamHist Adj. Mean SE
-0.11
0.39
0.47
0.29
0.66
False
True

0.38

0.41

0.59

0.4

0.77
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Decision Doctor Vs Self Fully Adjusted Model Differences due to Family History
The overall Type III p=0.041
Contrast
Estimate SE
OddsRatio CI95Min CI95Max p-value
0.49
0.24
1.63
1.02
2.61
0.041
True - False
For doctor versus self, inclusion of family history was assessed by adding it to the model
and comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision doctor versus self, fully
adjusted model differences due to family history was illustrated in table 16 and showed
significant influence in the fully adjusted model of decision doctor versus self for patients
with family history of breast cancer.
Table 17
Decision Doctor Vs Self Fully Adjusted Model Logistic Regression for Age
Adj.
SE
Probability CI95Min CI95Max
Age
Mean
-0.11
0.4
0.47
0.29
0.66
31 to 40 years old
41 to 50 years old
20 to 30 years old
51 to 60 years old

0.16

0.37

0.54

0.36

0.71

0.59

0.8

0.64

0.27

0.9

0.4

0.47

0.29

0.67

-0.1
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Decision Doctor Vs Self Fully Adjusted Model Differences due to Age
The overall Type III p=0.62
Estim SE
OddsR CI95
Contrast
ate

atio

CI95
Max

Min

pvalue

41 to 50 years old-31 to 40 years old

0.27

0.29

1.3

0.74

2.3

0.80

20 to 30 years old - 31 to 40 years old

0.69

0.76

2

0.45

8.95

0.80

20 to 30 years old - 41 to 50 years old

0.43

0.75

1.54

0.35

6.66

0.94

51 to 60 years old - 31 to 40 years old

0

0.32

1

0.54

1.88

1

51 to 60 years old - 41 to 50 years old

-0.26

0.29

0.77

0.44

1.35

0.80

51 to 60 years old - 20 to 30 years old

-0.69

0.76

0.5

0.11

2.23

0.80

For doctor versus self, inclusion of age was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision doctor versus self, fully
adjusted model differences due to age was illustrated in table 17 and showed no
significant influence in the fully adjusted model of decision doctor versus self despite the
age range of the patients.
Table 18
Decision Doctor Vs Self Fully Adjusted Model Logistic Regression for Race
Adj.
SE
Probability CI95Min CI95Max
Race
Mean
0.35
0.33
0.59
0.42
0.73
White or Caucasian
Hispanic/Latino
Black or African American
Asian or Pacific Islander
Other

-0.23

0.46

0.44

0.24

0.66

-0.32

0.66

0.42

0.17

0.72

0.39

0.68

0.6

0.28

0.85

0.49

0.81

0.62

0.25

0.89
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Decision Doctor Vs Self Fully Adjusted Model Differences due to Race
The overall Type III p=0.51
Estimat SE
OddsRati CI95Mi
Contrast
e

o

n

CI95Ma
x

pvalue

Hispanic/Latino – White or Caucasian

-0.58

0.38

0.56

0.27

1.18

0.55

Black or African American – Hispanic/Latino

-0.67

0.61

0.51

0.16

1.69

0.81

Black or African American - Hispanic/Latino

-0.09

0.68

0.92

0.24

3.45

1

Asian or Pacific Islander - White or Caucasian

0.04

0.61

1.04

0.31

3.46

1

0.62

0.69

1.85

0.48

7.16

0.90

Asian or Pacific Islander - Black or African
American

0.71

0.85

2.03

0.38

10.72

0.92

Other - White or Caucasian

0.14

0.76

1.15

0.26

5.11

Other - Hispanic/Latino

0.72

0.83

2.05

0.4

10.46

0.91

Other - Black or African American

0.8

0.95

2.24

0.34

14.53

0.92

Other - Asian or Pacific Islander

0.1

0.96

1.1

0.17

7.2

Asian or Pacific Islander - Hispanic/Latino

1

1

For doctor versus self, inclusion of race was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision doctor versus self, fully
adjusted model differences due to race was illustrated in table 18 and showed no
significant influence in the fully adjusted model of decision doctor versus self despite the
race of the patients.
Table 19
Decision Doctor Vs Self Fully Adjusted Model Logistic Regression for Partner
SE
Probability
CI95Min CI95Max
Partner Adj. Mean
-0.02
0.46
0.5
0.29
0.71
False
True

0.29

0.38

0.57

0.39

0.74
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Decision Doctor Vs Self Fully Adjusted Model Differences due to Partner
The overall Type III p=0.35
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
0.31
0.33
1.36
0.71
2.61
0.35
TRUE-FALSE

For doctor versus self, inclusion of partner was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision doctor versus self, fully
adjusted model differences due to partner was illustrated in table 19 and showed no
significant influence in the fully adjusted model of decision doctor versus self despite
whether the patient has a partner or not.
Table 20
Decision Doctor Vs Self Fully Adjusted Model Logistic Regression for Education
Adj.
SE
Probability CI95Min CI95Max
Education
Mean
-0.39
0.54
0.4
0.19
0.66
High school or GED
Trade or technical school
Junior college, or some college
College graduate
Postgraduate work or degree

0.32

0.68

0.58

0.27

0.84

0.22

0.46

0.55

0.33

0.75

0.18

0.4

0.54

0.35

0.72

0.36

0.41

0.59

0.39

0.76
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Decision Doctor Vs Self Fully Adjusted Model Differences due to Education
The overall Type III p=0.57
Estimat SE
OddsRati CI95Mi CI95Ma
Contrast
e

o

n

x

pvalue

Trade or technical school-High school, or GED

0.71

0.75

2.04

0.47

8.8

0.87

Junior college, or some college-High school or GED

0.61

0.49

1.84

0.71

4.77

0.72

0.68

0.9

0.24

3.42

1

0.57

0.44

1.77

0.74

4.22

0.70

College graduate-Trade or technical school

-0.15

0.64

0.86

0.25

3.05

1

College graduate-Junior college or some college

-0.04

0.34

0.96

0.49

1.87

1

0.75

0.45

2.12

0.89

5.09

0.44

Junior college, or some college-Trade or technical
school
College graduate-High school or GED

Postgraduate work or degree-High school or GED
Postgraduate work or degree-Trade or technical school

-0.1

0.04

0.65

1.04

0.29

3.71

1

Postgraduate work or degree-Junior college or some
college

0.14

0.35

1.15

0.59

2.27

0.99

Postgraduate work or degree-College graduate

0.18

0.28

1.2

0.7

2.07

0.96

For doctor versus self, inclusion of education was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision doctor versus self, fully
adjusted model differences due to education was illustrated in table 20 and showed no
significant influence in the fully adjusted model of decision doctor versus self despite the
education levels of the patients.
Table 21
Decision Doctor Vs Self Fully Adjusted Model Logistic Regression for Receptor
Probability CI95Min CI95Max
Receptor Adj. Mean SE
0.01
0.45
0.5
0.29
0.71
FALSE
TRUE

0.27

0.38

0.57

0.38

0.73

83
Decision Doctor Vs Self Fully Adjusted Model Differences due to Receptor
The overall Type III p=0.40
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
0.26
0.31
1.3
0.71
2.39
0.40
TRUE-FALSE
For doctor versus self, inclusion of receptor was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision doctor versus self, fully
adjusted model differences due to receptor was illustrated in table 21 and showed no
significant influence in the fully adjusted model of decision doctor versus self despite the
receptor status of the patients.
Table 22
Decision Doctor Vs Self Fully Adjusted Model Logistic Regression for
Lymphatic_Invasion
SE
Probability CI95Min CI95Max
Lymphatic_Invasion Adj.
Mean
0.04
0.38
0.51
0.33
0.69
NEG
POS

0.23

0.44

0.56

0.35

0.75

Decision Doctor Vs Self Fully Adjusted Model Differences due to Lymphatic_Invasion
The overall Type III p=0.51
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
0.18
0.28
1.2
0.69
2.09
0.52
POS-NEG
For doctor versus self, inclusion of lymphatic invasion was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision doctor versus
self, fully adjusted model differences due to lymphatic invasion was illustrated in table 22
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and showed no significant influence in the fully adjusted model of decision doctor versus
self despite the lymphatic invasion whether it is positive or negative.
Table 23
Decision Doctor Vs Self Fully Adjusted Model Logistic Regression for DifDaySurg
Probability CI95Min CI95Max
DifDaySurg Adj. Mean SE
0.22
0.38
0.56
0.37
0.73
False
True

0.05

0.45

0.51

0.3

0.72

Decision Doctor Vs Self Fully Adjusted Model Differences due to DifDaySurg
The overall Type III p=0.59
Estimate SE
Odds Ratio CI95Min CI95Max p-value
Contrast
-0.17
0.32
0.84
0.45
1.58
0.59
TRUE-FALSE
For doctor versus self, inclusion of different day surgery was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision doctor versus
self, fully adjusted model differences due to different day surgery was illustrated in table
23 and showed no significant influence in the fully adjusted model of decision doctor
versus self despite the choice of the patients to have CPM the same day of the surgery or
in a different day of the surgery.
Table 24
Decision Doctor Vs Self Fully Adjusted Model Logistic Regression for Tumor Grade
Probability CI95Min CI95Max
Tumor Grade Adj. Mean SE
0.22
0.58
0.55
0.29
0.79
I
II
III

-0.05

0.42

0.49

0.29

0.68

0.24

0.36

0.56

0.39

0.72
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Decision Doctor Vs Self Fully Adjusted Model Differences due to Tumor Grade
The overall Type III p=0.53
OddsRatio CI95Min CI95Max p-value
Contrast Estimate SE
-0.27
0.5
0.76
0.29
2.04
0.85
II-I
III-I
III-II

0.02

0.51

1.02

0.37

2.78

1.00

0.29

0.27

1.33

0.79

2.25

0.53

For doctor versus self, inclusion of tumor grade was assessed by adding it to the model
and comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision doctor versus self, fully
adjusted model differences due to tumor grade was illustrated in table 24 and showed no
significant influence in the fully adjusted model of decision doctor versus self despite the
tumor grade.
Table 25
Decision Doctor Vs Self Fully Adjusted Model Logistic Regression for Path Stage
Probability CI95Min CI95Max
Path Stage Adj. Mean SE
0.63
0.47
0.65
0.43
0.83
0
I
II
III

0.21

0.41

0.55

0.36

0.73

-0.11

0.43

0.47

0.28

0.68

-0.18

0.49

0.46

0.24

0.69
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Decision Doctor Vs Self Fully Adjusted Model Differences due to Path Stage
The overall Type III p=0.22
OddsRatio CI95Min CI95Max p-value
Contrast Estimate SE
-0.42
0.35
0.66
0.33
1.3
0.63
I-0
II-0
II-I
III-0

-0.74

0.38

0.48

0.23

1

0.21

-0.33

0.29

0.72

0.41

1.27

0.67

-0.81

0.49

0.45

0.17

1.16

0.35

-0.39

0.4

0.68

0.31

1.5

0.77

-0.06

0.41

0.94

0.42

2.1

1

III-I
III-II
For doctor versus self, inclusion of pathological stage was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision doctor versus
self, fully adjusted model differences due to pathological stage was illustrated in table 25
showed no significant influence in the fully adjusted model of decision doctor versus self
despite the pathological stage of the tumor.
Table 26
Decision Partner Vs Self Fully Adjusted Model Logistic Regression
for Family History
Probability CI95Min CI95Max
FamHist Adj. Mean SE
-4.34
237,54
0.01
0
1
False
True

-3.45

237.54

0.03

0

1

Decision Partner Vs Self Fully Adjusted Model Differences due to Family History
The overall Type III p=0.014
Contrast
Estimate SE
OddsRatio CI95Min CI95Max p-value
0.88
0.36
2.42
1.2
4.89
0.014
True - False
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For partner versus self, inclusion of family history was assessed by adding it to the model
and comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision partner versus self, fully
adjusted model differences due to family history was illustrated in table 26 and showed
significant influence in the fully adjusted model of decision partner versus self for
patients with family history of breast cancer.
Table 27
Decision Partner Vs Self Fully Adjusted Model Logistic Regression for Age
Adj.
SE
Probability CI95Min CI95Max
Age
Mean
-3.8
237.54
0.02
0
1
31 to 40 years old
41 to 50 years old
20 to 30 years old
51 to 60 years old

-4.14

237.54

0.02

0

1

-3.46

237.54

0.03

0

1

-4.17

237.54

0.02

0

1
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Decision Partner Vs Self Fully Adjusted Model Differences due to Age
The overall Type III p=0.80
Estimat SE
OddsRati CI95Mi CI95Ma pContrast
e

o

n

x

value

41 to 50 years old-31 to 40 years old

-0.34

0.43

0.71

0.3

1.65

0.85

20 to 30 years old - 31 to 40 years old

0.34

1.35

1.4

0.1

19.74

1

20 to 30 years old - 41 to 50 years old

0.68

1.35

1.97

0.14

27.58

0.96

51 to 60 years old - 31 to 40 years old

-0.37

0.48

0.69

0.27

1.77

0.87

51 to 60 years old - 41 to 50 years old

-0.02

0.44

0.98

0.41

2.32

1

51 to 60 years old - 20 to 30 years old

-0.7

1.35

0.49

0.03

6.98

0.95

For partner versus self, inclusion of age was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision partner versus self, fully
adjusted model differences due to age was illustrated in table 27 and showed no
significant influence in the fully adjusted model of decision partner versus self despite the
age range of the patients.
Table 28
Decision Partner Vs Self Fully Adjusted Model Logistic Regression for Race
Adj. SE
Probability CI95Min CI95Max
Race
Mean
-0.85
0.54
0.3
0.13
0.55
White or Caucasian
Hispanic/Latino
Black or African American
Asian or Pacific Islander
Other

-0.98

0.71

0.27

0.09

0.6

-0.47

1.05

0.39

0.07

0.83

-0.53

0.91

0.37

0.09

0.78

0

0

NA

1187.69
16.64
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Decision Partner Vs Self Fully Adjusted Model Differences due to Race
The overall Type III p=0.98
Estim SE
Odds CI95
CI95M pContrast
ate
Hispanic/Latino – White or Caucasian

Ratio

Min

ax

value

-0.12

0.56

0.89

0.3

2.64

1

Black or African American – Hispanic/Latino

0.39

0.94

1.47

0.24

9.25

0.99

Black or African American - Hispanic/Latino

0.51

1.05

1.67

0.21

Asian or Pacific Islander - White or Caucasian

0.33

0.82

1.39

0.28

6.86

1

0.45

0.94

1.57

0.25

9.92

0.99

-0.06

1.22

0.94

0.09

10.35

1

Other - White or Caucasian

-15.79

1187.69

0

0

Inf

1

Other - Hispanic/Latino

-15.67

1187.69

0

0

Inf

1

Other - Black or African American

-16.18

1187.69

0

0

Inf

1

Other - Asian or Pacific Islander

-16.11

1187.69

0

0

Inf

1

Asian or Pacific Islander - Hispanic/Latino
Asian or Pacific Islander - Black or African
American

13.1

0.99

For partner versus self, inclusion of race was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision partner versus self, fully
adjusted model differences due to race was illustrated in table 28 and showed no
significant influence in the fully adjusted model of decision partner versus self despite the
race of the patients.
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Table 29
Decision Partner Vs Self Fully Adjusted Model Logistic Regression for Education
Adj. SE
Probability CI95Min CI95Max
Education
Mean
-4.07 237.54
0.02
0
1
High school or GED
Trade or technical school
Junior college, or some college
College graduate

-4.21

237.54

0.01

0

1

-3.51

237.54

0.03

0

1

-3.83

237.54

0.02

0

1

-3.84

237.54

0.02

0

1

Postgraduate work or degree

Decision Partner Vs Self Fully Adjusted Model Differences due to Education
The overall Type III p=0.92
Esti
SE
OddsRa CI95M CI95M
Contrast
mate
Trade or technical school-High school, or GED

tio

in

ax

pvalue

-0.14

1.12

0.87

0.1

7.75

1

0.56

0.75

1.75

0.4

7.64

0.95

0.7

0.99

2.01

0.29

14.08

0.96

0.24

0.69

1.27

0.33

4.93

1

0.38

0.94

1.46

0.23

9.21

1.00

-0.32

0.5

0.73

0.27

1.94

0.97

Postgraduate work or degree-High school or GED

0.23

0.71

1.26

0.31

5.09

1

Postgraduate work or degree-Trade or technical school

0.37

0.95

1.45

0.23

9.32

1

-0.32

0.51

0.72

0.27

1.95

0.97

0.43

1

0.43

2.31

1

Junior college, or some college-High school or GED
Junior college, or some college-Trade or technical
school
College graduate-High school or GED
College graduate-Trade or technical school
College graduate-Junior college or some college

Postgraduate work or degree-Junior college or some
college

0
Postgraduate work or degree-College graduate

For partner versus self, inclusion of education was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
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Criteria (AIC). The result of the logistic regression of decision partner versus self, fully
adjusted model differences due to education was illustrated in table 29 and showed no
significant influence in the fully adjusted model of decision partner versus self despite the
education levels of the patients.
Table 30
Decision Partner Vs Self Fully Adjusted Model Logistic Regression for Receptor
Probability CI95Min CI95Max
Receptor Adj. Mean SE
-3.97
237.54
0.02
0
1
FALSE
TRUE

-3.82

237.54

0.02

0

1

Decision Partner Vs Self Fully Adjusted Model Differences due to Receptor
The overall Type III p=0.75
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
0.14
0.45
1.16
0.48
2.8
0.75
TRUE-FALSE
For partner versus self, inclusion of receptor was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision partner versus self, fully
adjusted model differences due to receptor was illustrated in table 30 and showed no
significant influence in the fully adjusted model of decision partner versus self despite the
receptor status of the patients.
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Table 31
Decision Partner Vs Self Fully Adjusted Model Logistic Regression for
Lymphatic_Invasion
Probability CI95Min CI95Max
Lymphatic_Invasion Adj. SE
Mean
-4.19 237.54
0.01
0
1
NEG
-3.59

POS

237.54

0.03

0

1

Decision Partner Vs Self Fully Adjusted Model Differences due to Lymphatic_Invasion
The overall Type III p=0.15
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
0.6
0.42
1.83
0.8
4.17
0.15
POS-NEG
For partner versus self, inclusion of lymphatic invasion was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision partner versus
self, fully adjusted model differences due to lymphatic invasion was illustrated in table 31
and showed no significant influence in the fully adjusted model of decision partner versus
self despite the lymphatic invasion whether it is positive or negative.
Table 32
Decision Partner Vs Self Fully Adjusted Model Logistic Regression for DifDaySurg
Probability CI95Min CI95Max
DifDaySurg Adj. Mean SE
-3.58
237.54
0.03
0
1
False
True

-4.2

327.54

0.01

0

1

Decision Partner Vs Self Fully Adjusted Model Differences due to DifDaySurg
The overall Type III p=0.22
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
-0.62
0.51
0.54
0.2
1.46
0.22
TRUE-FALSE
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For partner versus self, inclusion of different day surgery was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision partner versus
self, fully adjusted model differences due to different day surgery was illustrated in table
32 and showed no significant influence in the fully adjusted model of decision partner
versus self despite the choice of the patients to have CPM the same day of the surgery or
in a different day of the surgery.
Table 33
Decision Partner Vs Self Fully Adjusted Model Logistic Regression for Tumor Grade
Probability CI95Min CI95Max
Tumor Grade Adj. Mean SE
-3.45
237.54
0.03
0
1
I
II
III

-4.18

237.54

0.02

0

1

-4.04

237.54

0.02

0

1

Decision Partner Vs Self Fully Adjusted Model Differences due to Tumor Grade
The overall Type III p=0.62
OddsRatio CI95Min CI95Max p-value
Contrast Estimate SE
-0.73
0.75
0.48
0.11
2.11
0.60
II-I
III-I
III-II

-0.59

0.77

0.55

0.12

2.52

0.73

0.14

0.42

1.15

0.51

2.59

0.94

For partner versus self, inclusion of tumor grade was assessed by adding it to the model
and comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision partner versus self, fully
adjusted model differences due to tumor grade was illustrated in table 33 and showed no
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significant influence in the fully adjusted model of decision partner versus self despite the
tumor grade.
Table 34
Decision Partner Vs Self Fully Adjusted Model Logistic Regression for Path Stage
Probability CI95Min CI95Max
Path Stage Adj. Mean SE
-3.48
237.54
0.03
0
1
0
I
II
III

-3.55

237.54

0.03

0

1

-4.38

237.54

0.01

0

1

-4.16

237.54

0.02

0

1

Decision Partner Vs Self Fully Adjusted Model Differences due to Path Stage
The overall Type III p=0.31
OddsRatio CI95Min CI95Max p-value
Contrast Estimate SE
-0.07
0.48
0.93
0.36
2.39
1
I-0
II-0
II-I
III-0

-0.89

0.58

0.41

0.13

1.29

0.42

-0.82

0.48

0.44

0.17

1.13

0.32

-0.68

0.73

0.51

0.12

2.11

0.79

-0.61

0.64

0.55

0.15

1.92

0.78

0.22

0.68

1.24

0.33

4.7

0.99

III-I
III-II
For partner versus self, inclusion of pathological stage was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision partner versus
self, fully adjusted model differences due to pathological stage was illustrated in table 34
showed no significant influence in the fully adjusted model of decision partner versus self
despite the pathological stage of the tumor.
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Table 35
Decision Media Vs Self Fully Adjusted Model Logistic Regression
for Family History
Probability CI95Min CI95Max
FamHist Adj. Mean SE
-4.39
213.31
0.01
0
1
False
True

-4.07

213.31

0.02

0

1

Decision Media Vs Self Fully Adjusted Model Differences due to Family History
The overall Type III p=0.44
Contrast
Estimate SE
OddsRatio CI95Min CI95Max p-value
0.32
0.41
1.37
0.61
3.1
0.44
True - False

For media versus self, inclusion of family history was assessed by adding it to the model
and comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision media versus self, fully
adjusted model differences due to family history was illustrated in table 35 and showed
no significant influence in the fully adjusted model of decision media versus self for
patients with family history of breast cancer
Table 36
Decision Media Vs Self Fully Adjusted Model Logistic Regression for Age
Adj.
SE
Probability CI95Min CI95Max
Age
Mean
-4.22 213.31
0.01
0
1
31 to 40 years old
41 to 50 years old
20 to 30 years old
51 to 60 years old

-4.36

213.31

0.01

0

1

-3.47

213.31

0.03

0

1

-4.88

213.31

0.01

0

1
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Decision Media Vs Self Fully Adjusted Model Differences due to Age
The overall Type III p=0.52
Estim SE
OddsR CI95
Contrast
ate

atio

CI95
Max

Min

pvalue

41 to 50 years old-31 to 40 years old

-0.14

0.48

0.87

0.34

2.23

0.99

20 to 30 years old - 31 to 40 years old

0.75

1.05

2.13

0.27

16.81

0.89

20 to 30 years old - 41 to 50 years old

0.89

1.05

2.44

0.31

19.08

0.83

51 to 60 years old - 31 to 40 years old

-0.66

0.58

0.52

0.16

1.62

0.67

51 to 60 years old - 41 to 50 years old

-0.52

0.55

0.59

0.2

1.73

0.77

51 to 60 years old - 20 to 30 years old

-1.42

1.09

0.24

0.03

2.05

0.56

For media versus self, inclusion of age was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision media versus self, fully
adjusted model differences due to age was illustrated in table 36 and showed no
significant influence in the fully adjusted model of decision Media versus self despite the
age range of the patients.
Table 37
Decision Media Vs Self Fully Adjusted Model Logistic Regression for Race
Adj.
SE
Probabi CI95Min CI95Max
Race
Mean
lity
-1.66
0.59
0.16
0.06
0.38
White or Caucasian
Hispanic/Latino
Black or African American
Asian or Pacific Islander

-2.03

0.87

0.12

0.02

0.42

-0.26

0.87

0.43

0.12

0.81

-0.96

0.96

0.28

0.05

0.71

0

0

1

-16.25

Other

1066.55
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Decision Media Vs Self Fully Adjusted Model Differences due to Race
The overall Type III p=0.33
Estim SE
Odds CI95
CI95Max
Contrast
ate
Hispanic/Latino – White or Caucasian

Ratio

Min

pval
ue

-0.37

0.69

0.69

0.18

Black or African American – Hispanic/Latino

1.39

0.77

4.03

0.9

18.1

0.36

Black or African American - Hispanic/Latino

1.77

0.96

5.87

0.9

38.41

0.35

Asian or Pacific Islander - White or Caucasian

0.69

0.81

2

0.41

9.85

0.91

1.07

1.02

2.91

0.4

21.32

0.83

-0.7

1.09

0.5

0.06

4.17

0.97

Other - White or Caucasian

-14.6

1066.55

0

0

Inf

1

Other - Hispanic/Latino

-14.22

1066.55

0

0

Inf

1

Other - Black or African American

-15.99

1066.55

0

0

Inf

1

Other - Asian or Pacific Islander

-15.29

1066.55

0

0

Inf

1

Asian or Pacific Islander - Hispanic/Latino
Asian or Pacific Islander - Black or African
American

2.66

0.98

For media versus self, inclusion of race was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision media versus self, fully
adjusted model differences due to race was illustrated in table 37 and showed no
significant influence in the fully adjusted model of decision media versus self despite the
race of the patients.
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Table 38
Decision Media Vs Self Fully Adjusted Model Logistic Regression
for Partner
Probability CI95Min CI95Max
Partner Adj.Mean SE
-4.39
213.31
0.01
0
1
False
True

-4.08

213.31

0.02

0

1

Decision Media Vs Self Fully Adjusted Model Differences due to Partner
The overall Type III p=0.63
Contrast
Estimate SE
OddsRatio CI95Min CI95Max p-value
0.31
0.64
1.37
0.39
4.8
0.63
True - False
For media versus self, inclusion of partner was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision media versus self, fully
adjusted model differences due to partner was illustrated in table 38 and showed no
significant influence in the fully adjusted model of decision media versus self despite
whether the patient has a partner or not.
Table 39
Decision Media Vs Self Fully Adjusted Model Logistic Regression for Education
Adj.Mean SE
Probability CI95Min CI95Max
Education
-4.66
213.31
0.01
0
1
High school or GED
Trade or technical school
Junior college, or some college
College graduate
Postgraduate work or degree

-4.7

213.31

0.01

0

1

-3.81

213.31

0.02

0

1

-3.85

213.31

0.02

0

1

-4.16

213.31

0.02

0

1
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Decision Media Vs Self Fully Adjusted Model Differences due to Education
The overall Type III p=0.80
Estim SE
Odds
CI95
CI95M pContrast
ate
Trade or technical school-High school, or GED

Ratio

Min

ax

val
ue

-0.04

1.44

0.96

0.06

16.01

1

Junior college, or some college-High school or GED

0.84

0.94

2.33

0.37

14.78

0.90

Junior college, some college-Trade or technical school

0.88

1.3

2.42

0.19

30.72

0.96

College graduate-High school or GED

0.81

0.86

2.25

0.41

12.24

0.88

0.85

1.21

2.34

0.22

24.91

0.96

-0.03

0.61

0.97

0.29

3.19

1

0.5

0.88

1.65

0.29

9.34

0.98

College graduate-Trade or technical school
College graduate-Junior college or some college
Postgraduate work or degree-High school or GED
Postgraduate work or degree-Trade or technical school

0.54

1.22

1.72

0.16

Postgraduate work or degree-Junior college or some
college

18.8

0.99

-0.34

0.63

0.71

0.21

2.41

0.98

Postgraduate work or degree-College graduate

-0.31

0.47

0.73

0.29

1.84

0.97

For media versus self, inclusion of education was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision media versus self, fully
adjusted model differences due to education was illustrated in table 39 and showed no
significant influence in the fully adjusted model of decision media versus self despite the
education levels of the patients.
Table 40
Decision Media Vs Self Fully Adjusted Model Logistic Regression for Receptor
Probability CI95Min CI95Max
Receptor Adj.Mean SE
-4.16
213.31
0.02
0
1
FALSE
TRUE

-4.31

213.31

0.01

0

1
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Decision Media Vs Self Fully Adjusted Model Differences due to Receptor
The overall Type III p=0.78
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
-0.14
0.53
0.87
0.31
2.44
0.79
TRUE-FALSE
For media versus self, inclusion of receptor was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision media versus self, fully
adjusted model differences due to receptor was illustrated in table 40 and showed no
significant influence in the fully adjusted model of decision media versus self despite the
receptor status of the patients.
Table 41
Decision Media Vs Self Fully Adjusted Model Logistic Regression for
Lymphatic_Invasion
Probability CI95Min CI95Max
Lymphatic_Invasion Adj.Mean SE
-4.29
213.31
0.01
0
1
NEG
POS

-4.18

213.31

0.02

0

1

Decision Media Vs Self Fully Adjusted Model Differences due to Lymphatic_Invasion
The overall Type III p=0.84
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
0.11
0.52
1.11
0.4
3.07
0.84
POS-NEG
For media versus self, inclusion of lymphatic invasion was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision media versus
self, fully adjusted model differences due to lymphatic invasion was illustrated in table 41
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and showed no significant influence in the fully adjusted model of decision media versus
self despite the lymphatic invasion whether it is positive or negative.
Table 42
Decision Media Vs Self Fully Adjusted Model Logistic Regression for DifDaySurg
Probability CI95Min CI95Max
DifDaySurg Adj. Mean SE
-4.13
213.31
0.02
0
1
False
True

-4.34

213.31

0.01

0

1

Decision Media Vs Self Fully Adjusted Model Differences due to DifDaySurg
The overall Type III p=0.72
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
-0.22
0.61
0.81
0.24
2.68
0.72
TRUE-FALSE

For media versus self, inclusion of different day surgery was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision media versus
self, fully adjusted model differences due to different day surgery was illustrated in table
42 and showed no significant influence in the fully adjusted model of decision media
versus self despite the choice of the patients to have CPM the same day of the surgery or
in a different day of the surgery.
Table 43
Decision Media Vs Self Fully Adjusted Model Logistic Regression for Tumor Grade
Probability CI95Min CI95Max
Tumor Grade Adj. Mean SE
-3.48
213.31
0.03
0
1
I
II
III

-4.21

213.31

0.01

0

1

-5

213.31

0.01

0

1
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Decision Media Vs Self Fully Adjusted Model Differences due to Tumor Grade
The overall Type III p=0.12
OddsRatio CI95Min CI95Max p-value
Contrast Estimate SE
-0.73
0.75
0.48
0.11
2.11
0.60
II-I
III-I
III-II

-1.52

0.82

0.22

0.04

1.09

0.15

-0.79

0.49

0.45

0.17

1.18

0.24

For media versus self, inclusion of tumor grade was assessed by adding it to the model
and comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision media versus self, fully
adjusted model differences due to tumor grade was illustrated in table 43 and showed no
significant influence in the fully adjusted model of decision media versus self despite the
tumor grade.
Table 44
Decision Media Vs Self Fully Adjusted Model Logistic Regression for Path Stage
Probability CI95Min CI95Max
Path Stage Adj. Mean SE
-3.22
213.31
0.04
0
1
0
I
II
III

-4.05

213.31

0.02

0

1

-4.78

213.31

0.01

0

1

-4.89

213.31

0.01

0

1
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Decision Media Vs Self Fully Adjusted Model Differences due to Path Stage
The overall Type III p=0.10
OddsRatio CI95Min CI95Max p-value
Contrast Estimate SE
-0.82
0.53
0.44
0.16
1.24
0.40
I-0
II-0
II-I
III-0

-1.55

0.68

0.21

0.06

0.8

0.10

-0.73

0.57

0.48

0.16

1.48

0.58

-1.66

0.93

0.19

0.03

1.17

0.28

-0.84

0.84

0.43

0.08

2.26

0.75

-0.11

0.9

0.9

0.15

5.25

1

III-I
III-II
For media versus self, inclusion of pathological stage was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision media versus
self, fully adjusted model differences due to pathological stage was illustrated in table 44
and showed no significant influence in the fully adjusted model of decision media
versus self despite the pathological stage of the tumor.
Table 45
Decision Any Vs Self Fully Adjusted Model Logistic Regression
for Family History
Probability CI95Min CI95Max
FamHist Adj. Mean SE
0.67
0.45
0.66
0.45
0.82
False
True

1.19

0.47

0.77

0.57

0.89

Decision Any Vs Self Fully Adjusted Model Differences due to Family History
The overall Type III p=0.044
Contrast
Estimate SE
OddsRatio CI95Min CI95Max p-value
0.52
0.26
1.68
1.01
2.79
0.044
True - False
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For any versus self, inclusion of family history was assessed by adding it to the model
and comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision any versus self, fully
adjusted model differences due to family history was illustrated in table 45 and showed
significant influence in the fully adjusted model of decision any versus self for patients
with family history of breast cancer.
Table 46
Decision Any Vs Self Fully Adjusted Model Logistic Regression for Age
Adj.
SE
Probability CI95Min CI95Max
Age
Mean
0.47
0.4
0.62
0.42
0.78
31 to 40 years old
41 to 50 years old
20 to 30 years old
51 to 60 years old

0.57

0.37

0.64

0.46

0.78

2.27

1.15

0.91

0.5

0.99

0.43

0.42

0.61

0.4

0.78

Decision Any Vs Self Fully Adjusted Model Differences due to Age
The overall Type III p=0.43
Estim SE
OddsR
Contrast
ate

atio

CI95
Min

41 to 50 years old-31 to 40 years old

0.1

0.31

1.1

0.6

20 to 30 years old - 31 to 40 years old

1.8

1.13

6.03

20 to 30 years old - 41 to 50 years old

1.7

1.11

51 to 60 years old - 31 to 40 years old

-0.04

51 to 60 years old - 41 to 50 years old
51 to 60 years old - 20 to 30 years old

CI95
Max

pvalue

2.03

0.99

0.66

55

0.38

5.47

0.62

48.55

0.42

0.34

0.96

0.49

1.88

1.00

-0.14

0.31

0.87

0.47

1.6

0.97

-1.84

1.13

0.16

0.02

1.44

0.36

For any versus self, inclusion of age was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
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Criteria (AIC). The result of the logistic regression of decision any versus self, fully
adjusted model differences due to age was illustrated in table 46 and showed no
significant influence in the fully adjusted model of decision any versus self despite the
age range of the patients.
Table 47
Decision Any Vs Self Fully Adjusted Model Logistic Regression for Race
Adj.
SE
Probability CI95Min CI95Max
Race
Mean
1.06
0.39
0.74
0.58
0.86
White or Caucasian
Hispanic/Latino
Black or African American
Asian or Pacific Islander
Other

0.66

0.52

0.66

0.41

0.84

1.23

0.8

0.77

0.42

0.94

0.79

0.7

0.69

0.36

0.9

0.93

0.84

0.72

0.33

0.93
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Decision AnyVs Self Fully Adjusted Model Differences due to Race
The overall Type III p=0.88
Estima SE
OddsRat CI95M
Contrast
te

io

in

CI95M
ax

pvalue

Hispanic/Latino – White or Caucasian

-0.4

0.41

0.67

0.3

1.51

0.87

Black or African American – Hispanic/Latino

0.16

0.72

1.18

0.29

4.84

1.00

Black or African American - Hispanic/Latino

0.57

0.8

1.76

0.37

8.39

0.95

-0.27

0.62

0.76

0.23

2.59

0.99

0.13

0.71

1.14

0.28

4.61

1

-0.43

0.93

0.65

0.1

4.05

0.99

-0.14

0.76

0.87

0.2

3.88

1

0.27

0.85

1.3

0.25

6.85

1.00

-0.3

1.03

0.74

0.1

5.58

1.00

0.13

0.96

1.14

0.17

7.52

1

Asian or Pacific Islander - White or
Caucasian
Asian or Pacific Islander - Hispanic/Latino
Asian or Pacific Islander - Black or African
American
Other - White or Caucasian
Other - Hispanic/Latino
Other - Black or African American
Other - Asian or Pacific Islander

For any versus self, inclusion of race was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision any versus self, fully
adjusted model differences due to race was illustrated in table 47 and showed no
significant influence in the fully adjusted model of decision any versus self despite the
race of the patients.
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Table 48
Decision Any Vs Self Fully Adjusted Model Logistic Regression for Education
Adj.
SE
Probability CI95Min CI95Max
Education
Mean
0.22
0.6
0.56
0.28
0.8
High school or GED
Trade or technical school
Junior college, or some college
College graduate

1.18

0.73

0.77

0.44

0.93

1.21

0.53

0.77

0.54

0.9

0.94

0.46

0.72

0.51

0.86

1.11

0.48

0.75

0.54

0.89

Postgraduate work or degree

Decision Any Vs Self Fully Adjusted Model Differences due to Education
The overall Type III p=0.39
Esti
SE
OddsRa CI95M CI95M
Contrast
0.79

2.61

0.56

Junior college, or some college-High school or GED

0.99

0.52

2.69

0.96

7.5

0.32

Junior college, or some college-Trade or technical
school

0.03

0.71

1.03

0.25

4.19

1

College graduate-High school or GED

0.72

0.47

2.06

0.82

5.2

0.55

College graduate-Trade or technical school

-0.24

0.68

0.79

0.21

2.97

1.00

College graduate-Junior college or some college

-0.27

0.36

0.77

0.38

1.55

0.95

0.89

0.48

2.42

0.94

6.22

0.36

Trade or technical school-High school, or GED

Postgraduate work or degree-High school or GED
Postgraduate work or degree-Trade or technical school

tio

in

ax
12.16

pvalue
0.74

mate
0.96

-0.07

0.68

0.93

0.24

3.55

1

Postgraduate work or degree-Junior college or some
college

-0.1

0.37

0.9

0.43

1.88

1.00

Postgraduate work or degree-College graduate

0.16

0.3

1.18

0.68

2.12

0.98

For any versus self, inclusion of education was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
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Criteria (AIC). The result of the logistic regression of decision any versus self, fully
adjusted model differences due to education was illustrated in table 48 showed no
significant influence in the fully adjusted model of decision any versus self despite the
education levels of the patients.
Table 49
Decision Any Vs Self Fully Adjusted Model Logistic Regression for Receptor
Probability CI95Min CI95Max
Receptor Adj. Mean SE
-0.79
0.5
0.69
0.45
0.85
False
True

1.08

0.44

0.75

0.55

0.88

Decision Any Vs Self Fully Adjusted Model Differences due to Receptor
The overall Type III p=0.38
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
0.3
0.34
1.35
0.69
2.62
0.38
TRUE-FALSE
For any versus self, inclusion of receptor was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision any versus self, fully
adjusted model differences due to receptor was illustrated in table 48 showed no
significant influence in the fully adjusted model of decision any versus self despite the
receptor status of the patients.
Table 50
Decision Any Vs Self Fully Adjusted Model Logistic Regression for Lymphatic_Invasion
SE
Probability CI95Min CI95Max
Lymphatic_Invasion Adj.
Mean
0.89
0.44
0.71
0.51
0.85
NEG
POS

0.98

0.49

0.73

0.5

0.88
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Decision Any Vs Self Fully Adjusted Model Differences due to Lymphatic_Invasion
The overall Type III p=0.76
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
0.09
0.3
1.1
0.61
1.97
0.76
POS-NEG
For any versus self, inclusion of lymphatic invasion was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision any versus
self, fully adjusted model differences due to lymphatic invasion was illustrated in table 50
and showed no significant influence in the fully adjusted model of decision any versus
self despite the lymphatic invasion whether it is positive or negative.
Table 51
Decision Any Vs Self Fully Adjusted Model Logistic Regression for DifDaySurg
Probability CI95Min CI95Max
DifDaySurg Adj. Mean SE
1.05
0.44
0.74
0.55
0.87
False
True

0.82

0.5

0.69

0.46

0.86

Decision Any Vs Self Fully Adjusted Model Differences due to DifDaySurg
The overall Type III p=0.50
Estimate SE
OddsRatio CI95Min CI95Max p-value
Contrast
-0.22
0.33
0.8
0.42
1.54
0.50
TRUE-FALSE
For any versus self, inclusion of different day surgery was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision any versus
self, fully adjusted model differences due to different day surgery was illustrated in table
50 and showed no significant influence in the fully adjusted model of decision any versus
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self despite the choice of the patients to have CPM the same day of the surgery or in a
different day of the surgery.
Table 52
Decision Any Vs Self Fully Adjusted Model Logistic Regression for Tumor Grade
Probability CI95Min CI95Max
Tumor Grade Adj. Mean SE
0.95
0.64
0.72
0.43
0.9
I
II
III

0.89

0.48

0.71

0.49

0.86

0.96

0.41

0.72

0.54

0.85

Decision Any Vs Self Fully Adjusted Model Differences due to Tumor Grade
The overall Type III p=0.97
OddsRatio CI95Min CI95Max p-value
Contrast Estimate SE
-0.06
0.52
0.94
0.34
2.63
0.99
II-I
III-I
III-II

0

0.54

1

0.35

2.89

1

0.06

0.29

1.07

0.61

1.87

0.97

For any versus self, inclusion of tumor grade was assessed by adding it to the model and
comparing it to the model without the covariate based upon the Akaike Information
Criteria (AIC). The result of the logistic regression of decision any versus self, fully
adjusted model differences due to tumor grade was illustrated in table 52 showed no
significant influence in the fully adjusted model of decision any versus self despite the
tumor grade.
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Table 53
Decision Any Vs Self Fully Adjusted Model Logistic Regression for Path Stage
Probability CI95Min CI95Max
Path Stage Adj. Mean SE
1.87
0.57
0.87
0.68
0.95
0
I
II
III

0.9

0.46

0.71

0.5

0.86

0.64

0.48

0.65

0.42

0.83

0.33

0.53

0.58

0.33

0.8

Decision Any Vs Self Fully Adjusted Model Differences due to Path Stage
The overall Type III p=0.023
OddsRatio CI95Min CI95Max p-value
Contrast Estimate SE
-0.98
0.41
0.38
0.17
0.85
0.08
I-0
II-0
II-I
III-0

-1.23

0.45

0.29

0.12

0.7

0.031

-0.26

0.3

0.77

0.42

1.4

0.83

-1.54

0.54

0.21

0.07

0.61

0.021

-0.57

0.41

0.57

0.25

1.27

0.51

-0.31

0.42

0.73

0.32

1.66

0.88

III-I
III-II

For any versus self, inclusion of pathological stage was assessed by adding it to the
model and comparing it to the model without the covariate based upon the Akaike
Information Criteria (AIC). The result of the logistic regression of decision any versus
self, fully adjusted model differences due to pathological stage was illustrated in table 53
and showed significant influence in the fully adjusted model of decision any versus self
when it came to the pathological stage of the tumor especially for patients with stage I0; II-0 and III-0 .
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Summary
Despite not being candidates for CPM, women with stage 0 to III early stage
unilateral breast cancer ages 20-60 years old who underwent CPM at MD Anderson
Cancer Center between January of 2010 and December of 2017 opted to have this
irreversible surgery. 205 out of 345
patients reported some doctor influence on the CPM decision. Sixty percent of
patients’ decisions were influenced by doctors. The model also showed that patients with
a family history of breast cancer had significantly higher odds of doctor-influence than
those without (p=.029, .040 with Hommel adjustment). 54 out of 190 patients with
partners reported some partner influence on the CPM decision. Twenty-eight percent of
patients’ decisions were influenced by partners. The model also showed that patients
with a family history of breast cancer had significantly higher odds of partner-influence
than those without (p=.023, .040 with Hommel adjustment). 36 out of 213 patients
reported some level of media influence on the CPM decision. Seventeen percent of
patients’ decisions were influenced by media. 227 out of 35 patients reported some level
of any influence on the CPM decision. Sixty-eight percent of patients’ decisions were
influenced by some combination of doctor, partner, or media. The model also showed
that patients with a family history of breast cancer had significantly higher odds of anyinfluence than those without (p=.040, .040 with Hommel adjustment).
No matter how small their risk was to develop contralateral breast cancer CBC), these
women chose developing CBC as their principal concern. The analysis demonstrates that
partners, physicians, and media had significant influence on the decision-making process
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of women with unilateral breast cancer to undergo CPM. In Chapter 5, I will discuss the
interpretation of the findings, limitations, recommendations, and implications of this
research.
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Chapter 5: Discussion, Conclusions, and Recommendations
The purpose of this study was to assess the influence of the physician, partner,
and media on women’s decision making with regards to the utilization of CPM among
women with early stage unilateral breast cancer and to determine to what extent their
decision was influenced by their physician, partner, and media. Despite not being
candidates for CPM, the results of this study indicated that women with stage 0 to III
early stage unilateral breast cancer ages 20-60 years old who underwent CPM at MD
Anderson Cancer Center between January of 2010 and December of 2017 who opted to
have this irreversible surgery reported not making the decision alone. Key findings of this
study are that partners, physicians, and media all had significant influence (p < 0.005) on
the decision-making process of women with unilateral breast cancer to undergo CPM.
Chapter 5 gives a final overview of the findings and its interpretation in the context of the
theoretical shared decision-making theory, limitations to generalizability, implications of
the study, recommendations for future research, and the impact of the study for positive
social change.
Interpretation of the Findings
CPM is one of many decisions that involve a choice where the outcome is not
certain. Patients should make an informed decision when it comes to this irreversible
procedure. Shared decision-making theory was used in order to resolve the confliction
between patient self-determination and practitioners’ responsibility and to confirm that
decisions are evidence-based and in patients’ interests (Brown & Salmon, 2018). The
shared model of decision making is the derivative of the normative decision theory and
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was used in my research study as the theoretical framework. Breast cancer patients are
consumers of medical care and have the right to actively participate in the decisionmaking process concerning treatment choices and risk reduction strategies. The
normative decision theory includes an active attempt to engage patient values in the
decision-making process. In order to accomplish this goal, patients should be provided
with decision aids such as informative brochures, videos, computer programs, as well as
physicians inputs.
Breast cancer patients should be provided with enough information and
opportunity to decide among treatment options consistent with the informed consent
process. Treatment options should be discussed with a patient in a culturally competent
manner, including the option of no treatment at all. Discussion should include all current
treatments a consumer may be undergoing and risks, benefits, and consequences to
treatment or non-treatment. Patients should be given the opportunity to refuse treatment
and to express preferences about future treatment decisions.
Achieving shared decision-making depends on building a good relationship
between the physician and the patients in the clinical encounter in order for the
information to be shared with breast cancer patients and allow patients to express and
deliberate their preferences regarding their treatment options during the decision-making
process (Elwyn et al., 2012). The patient decision may be influenced by their partner,
physician, or the media, and patients should play an active role in making an informed
decision regarding the treatment options. The SDM approach gives patients and
physicians the opportunity to jointly decide which medical treatment option is best based

116
on current evidence and patient’s needs and preferences (Elwyn et al., 2012). Patients'
decision can be compromised and affected by the disease or the stressful situations such
as the new diagnosis of breast cancer; for this reason, patients should be provided with
tools and education that help them make an informed decision. The results of this study
emphasize that despite not being candidates for CPM, women with stage 0 to III early
stage unilateral breast cancer ages 20-60 years old who underwent CPM at MD Anderson
Cancer Center between January of 2010 and December of 2017 opted to have this
irreversible surgery. Two hundred five out of 345 patients reported some doctor influence
on the CPM decision, Fifty four out of 190 patients with partners reported some partner
influence on the CPM decision, this compares to 36 out of 213 patients who reported
some level of media (television, newspapers, social media, magazines, and radio)
influence on the CPM decision. When asked about the reason to have the CPM surgery,
50.5% (186) of the women cited breast cancer prevention as the main reason for choosing
CPM.
The findings of the study correlated with the literatures that show that regardless
of knowing that CPM does not improve survival rate, many women with unilateral breast
cancer are choosing this procedure in order to ease their fear and potentially extend their
lives (Rosenberg et al., 2013). Despite not being candidates for CPM, the result of the
study demonstrated that women with stage 0 to III early stage unilateral breast cancer
ages 20-60 years old who underwent CPM at MD Anderson Cancer Center between
January of 2010 and December of 2017 opted to have this irreversible surgery. The
analysis demonstrates that partners, physicians, and media had significant influence on
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the decision-making process of women with unilateral breast cancer to undergo CPM.
The findings could highlight the need for decision aid programs or tools that help breast
cancer women increase their knowledge of their treatment options, reduce their decisional
conflicts, and make informed decisions that align with their goals and values. It is
important for women with unilateral breast cancer to fully understand the benefits versus
the adverse effects of CPM and make an informed decision regarding this irreversible
surgical procedure.
Limitations of the Study
The limitation to the study is that the patients that were evaluated for the research
study are inherent to one single institution which might affect the external validity or the
generalizability of the study findings. The response bias that might affect my research;
the breast cancer patients can consciously or unconsciously give responses that they think
that the person conducting the research might want to see. In order to address the
response bias limitation, clear language was used in the survey to avoid any clarification
to certain questions, the questions were not framed in a way that I was most likely to get
the answer I wanted to hear, the amount of options were not confusing, and the reason for
conducting the survey was communicated in the introduction part of the survey.
Women were selected from the surgical breast cancer database at MD Anderson
Cancer Center. The alpha for the test of this model was set at 0.05. In order to achieve
power of 0.80 and a medium effect size, a sample of 384 was required in order to detect
differences in the research study.

118
The binary influence variables which formed the basis of these analyses were not
independent. Most patients reporting influence from partners or media also report
influence from doctors. Two-thirds of patients reported some form of influence; taken
together, the results suggest that a patient with a family history of breast cancer appears
more likely to consider external perspectives in her decision to have a CPM.
Recommendations
This study was needed because the findings of the study highlight the need for
developing a decision quality tool that helps women with early stage unilateral breast
cancer make informed decisions regarding their surgical choices. While researchers may
know the factors that are influencing the decision-making process of women with
unilateral breast cancer to undergo CPM, prospective research is needed in order to
develop a decision quality tool that helps women with unilateral breast cancer make an
informed decision regarding their surgical choice. The decision quality tool can be a
brochure that includes but not limited to the indication for the CPM procedure, the
necessity and the medically unnecessary indication of the procedure, doctor’s
recommendation, the pro and cons of the procedure, the complications, and frequently
asked questions, as well as feedbacks from patients who did and did not choose CPM.
The patient should have good knowledge regarding the irreversible procedure so they can
make a shared informed decision about their treatment options. Future qualitative studies
are needed in order to determine whether the decision to have a breast reconstruction was
the main reason why patients opted to undergo prophylactic mastectomy, and whether the
patients have knowledge of breast reconstruction surgery and complications.
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Implications
The potential contribution of the study to advance practice and promote positive
social change is that it could help in assessing the influence of the partner, physician, and
media on the decision of women with unilateral breast cancer who decided to undergo
CPM, and the findings could highlight the need of decision aids programs or tools that
help breast cancer women increase their knowledge of their treatment options, reduce
their decisional conflicts, and make informed decisions that align with their goals and
values. It is important for women with unilateral breast cancer to fully understand the
benefits versus the adverse effect of CPM and make an informed decision regarding the
irreversible surgical procedure. Evidence driven models are needed to better inform
women about their risk of contralateral breast cancer in order to empower them in their
active decision-making process (Yi et al., 2009). No matter how small the risk was for
study participants to develop contralateral breast cancer (CBC), these women choose
developing CBC as their principal concern for having CPM. Women should understand
their risk of local, contralateral and systemic recurrence and that opting to choose the
irreversible CPM procedure will not affect these risks equally (Rosenberg et al., 2015).
The normative decision theory includes an active attempt in order to engage
patient’s values in the decision-making process. In order to accomplish this goal, patients
are provided with decision aids such as informative brochures, videos, computer
programs, as well as physician’s inputs (Elwyn et al., 2012). This model is
conceptualized as providing the patient with both objective medical information
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incorporated with her subjective values and opinions (Elwyn et al., 2012). The shared
model of decision-making is the derivative of the normative decision theory. SDM should
not be confused by obtaining an informed consent from patient. Informed consent is
mandated by ethical guidelines; while SDM is a process by which the physician and the
patient consider valuable information regarding the medical problem in question which
may include treatment options and consequences, which allows the patients to consider
how the treatment plan can fit with their preferences for health states and outcomes.
When faced with life threatening diseases like breast cancer, patients might make
uninformed decisions regarding their treatment. Patients might also overestimate the
benefits of CPM and others may underestimate the severity of some of the side effects
associated with this procedure. It is important for women with unilateral breast cancer to
fully understand the benefits as well as the side effects that are associated with CPM in
order to make informed and supported decisions, based on accurate understanding of the
pros versus the cons of the procedure.
Decision-making surrounding early diagnosis of breast cancer, with respect to
CPM option, and by using a shared decision-making approach, gives patients and
physicians the opportunity to jointly decide which medical treatment option is best based
on current evidence and patient’s needs and preferences (Rosenberg, & Partridge, 2014).
A clinical educational instrument is important to help women with unilateral breast
cancer make informed decision regarding CPM, and to improve the quality of life of
breast cancer survivors. Providing patients with educational instrument will empower
them to be effective advocate of their health and the treatment options and better
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understand their health conditions. Many patients have limited health information which
can be more complicated when combined with fear and decision-making providing
vulnerable patients with an informational tool in a format that they can easily understand
could improve the quality of their medical care and promote informed decision-making.
Conclusion
When faced with life threatening diseases like breast cancer, patients might make
uninformed decisions regarding their treatment. They might also overestimate the
benefits of CPM and others may underestimate the severity of some of the side effects
associated with this procedure. It is important for women with unilateral breast cancer to
fully understand the benefits as well as the side effects that are associated with CPM in
order to make informed and supported decisions, based on accurate understanding of the
benefits versus the risks of the procedure. Decision-making surrounding early diagnosis
of breast cancer, with respect to CPM option, and by using a shared decision-making
approach, gives patients and physicians the opportunity to jointly decide which medical
treatment option is best based on current evidence. A clinical educational instrument
would be important to help women with unilateral breast cancer make informed decision
regarding CPM, and to improve the quality of life of breast cancer survivors.
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Appendix
Contralateral Prophylactic Mastectomy Survey
Living with Breast Cancer Risk: Survey of Experiences and Decision-Making Process
Please check the one best answer to each of the following questions, unless
instructed otherwise.

Your Breast Cancer Experience and Thoughts

1. Before your contralateral prophylactic mastectomy, how would you have described
your concern about developing breast cancer?


2
1
4
3

Very concerned
Concerned
Not very concerned
Not concerned at all

2. At the time of your prophylactic mastectomy, what was your marital status?


3
4
5
1
2

Married
Living together but unmarried
Separated or divorced
Widowed
Single, never married

3. What were your reasons for having a contralateral prophylactic mastectomy?
Please check all that apply.


3
4
5
1
2

Uncomfortably large breasts
Concerns about appearance
Family history of breast cancer
Prevent breast cancer
Other, please specify: __________________________________________

4. Which statement (s) best describes the decision about your contalateral prophylactic
mastectomy? Choose all that apply.
 I made the final decision to have surgery.
 I made the final decision to have surgery after seriously considering my doctor's
opinion.
3
My doctor and I shared responsibility for the final decision to have surgery.
1
2
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 My doctor made the final decision about my surgery, but seriously considered my
opinion.
5
My doctor made the final decision about my surgery.
4



I made the final decision to have surgery after seriously considering my partner's
opinion.
7
My partner made the final decision about my surgery.

6

5. Media Influence: Please choose one number to indicate whether or not the media had
influenced your decision making to undergo prophylactic mastectomy.

Not
At
All

A
Little
Bit

Somewhat

Quite
A Bit

Very
Much

1

2

3

4

5

6. Thinking back to six months after your prophylactic mastectomy, how satisfied were you
with your decision to have the surgery?


3
4
5
1
2

Very dissatisfied
Dissatisfied
Neither Satisfied or Dissatisfied
Satisfied
Very satisfied

7. Did you have breast reconstruction after your prophylactic mastectomy? Breast
reconstruction is a surgical procedure in which the breasts are recreated using implants
or tissue from the body.
 No.

0

 Yes, done in a separate surgery after the prophylactic mastectomy
2 Yes, done along with prophylactic mastectomy
1

8. I “yes” Have you had surgery to revise or repair your reconstruction?
0

No
 Yes, one or two times
2
Yes, multiple times
1

134

Your Life Right Now
9. Below is a list of statements that describe aspects of women’s lives, including thoughts
about your body and sexuality.

FREQUENCY
Please choose one number to indicate how true each
statement has been for you during the past 30 days.

Not
At
All

A
Littl
e
Bit

Som
ewhat

Quit
e
A
Bit

Ver
y
Mu
ch

a. I am able to enjoy life.

1

2

3

4

5

b. I am content with the quality of my life
right now.

1

2

3

4

5

c. I feel self-conscious about my appearance.

1

2

3

4

5

d. I am happy with my current weight.

1

2

3

4

5

e. I am satisfied with my appearance when
dressed.

1

2

3

4

5

f. I find it difficult to look at myself naked.

1

2

3

4

5

g. I am embarrassed for others to see my
body.

1

2

3

4

5

h. I am able to feel like a woman.

1

2

3

4

5

i. I feel sexually attractive.

1

2

3

4

5

j. I am satisfied with my sex life.

1

2

3

4

5
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A Few Details About You
10. What was your age at the time of prophylactic mastectomy?

2
3
4
1

20 to 30 years old
31 to 40 years old
41 to 50 years old
51 to 60 years old

11. To what race/ethnic group do you belong? Please check all that apply.


3
4
5
9
1
2

Asian or Pacific Islander, please specify:
Black or African American
Hispanic/Latino, please specify:
Native American or Alaskan Native
White or Caucasian
Other, please specify:

12. What is the highest level of education you have completed?


3
4
5
6
1
2

Less than or some high school
High school or GED
Trade or technical school
Junior college, or some college
College graduate
Postgraduate work or degree

13. On what date did you complete this questionnaire?

____/____/____ (month/day/year)
14. How long ago was your prophylactic mastectomy? (Please insert the number
of years)
___________Years ago.

Final Questions
15. Overall, how satisfied are you now with your decision to have contralateral prophylactic
mastectomy?
Very dissatisfied
Dissatisfied
Satisfied
Very satisfied
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16. What one thing do you wish you had known before your prophylactic mastectomy?
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

Thank you very much for completing the survey!

